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Abstract
To prevent potential autoimmunity, the thymus instructs developing T cells to discriminate
between self and non-self. This instruction is called central tolerance induction and purges
the T cell repertoire of self-reacting T cells. Fundamental for central tolerance induction
is the expression of otherwise tissue-restricted antigens in the thymus [1, 2]. The two main
mechanisms operating in central tolerance are clonal deletion of auto-reactive T cells and
deviation of these into the regulatory T cell lineage. While enormous progress has been
made in understanding the cellular and molecular basis of central tolerance, the exact pa-
rameters that determine whether an auto-reactive T cell is deleted or becomes a regulatory
T cell are not yet fully understood.
We have developed a class II-restricted T cell receptor-transgenic model (TCR-PLP1) to
study the modes of central tolerance induction to the self-antigen myelin proteolipid protein
(PLP) in the context of H-2b. PLP is the main component of the myelin sheath around
neurons and of particular interest as it a candidate auto-antigen in Multiple Sclerosis in
humans. Furthermore, it had been shown that intra-thymic expression of PLP is suﬃcient
to mediate tolerance [3]. Using this novel TCR-PLP1 transgenic mouse, we investigated
the modalities of central tolerance induction to a self-antigen expressed in the thymus at
physiological levels. We found PLP-speciﬁc T cells to be tolerised by clonal deletion and
concomitant deviation into the regulatory T cell lineage. Thymic medullary epithelial cell
(mTEC)-driven expression and direct presentation of the endogenous antigen PLP medi-
ated tolerance in an autonomous manner, whereas thymic dendritic cells were dispensable
for central tolerance induction to PLP. Furthermore, the autoimmune regulator AIRE con-
trolled tolerance induction to PLP by regulating PLP mRNA expression in mTEChi, albeit
PLP is not regarded as classical AIRE-dependent antigen. We could also provide evidence,
that central tolerance might act in a dedicated time-window. We found negative selection
of TCR-PLP1+ CD4SP cells to begin at day 3, while PLP-speciﬁc regulatory T cells accu-
mulated only after 1 week after birth. Strikingly, we observed a loss of central tolerance
induction to PLP at the age of 6 weeks. Age-dependency was not yet considered closely for
central tolerance induction and expands its complexity for yet another aspect.

Zusammenfassung
Um der Entwicklung von Autoimmunität entgegenzuwirken, muss der Thymus neu entste-
henden T-Zellen die Fähigkeit mitgeben, zwischen körpereigenen und körperfremden Struk-
turen zu diﬀerenzieren. Dieser Vorgang, der als zentrale Toleranzentwicklung bezeichnet
wird, identiﬁziert jene T-Zellen, die auf körpereigene Strukturen reagieren und eliminiert
sie. Fundamentale Grundlage ist hierbei die Expression gewebespeziﬁscher Antigene im
Thymus [1, 2]. Zentrale Toleranz wird hauptsächlich über zwei Mechanismen vermittelt,
einerseits über die Beseitigung autoreaktiver T-Zell-Klone (clonal deletion), zum anderen
über ein Umleiten der identiﬁzierten Zellen in die regulatorische T-Zelllinie (Treg induc-
tion). Während zentrale Toleranz auf der zellulären und molekularen Ebene bereits recht
gut verstanden wird, ist noch nicht vollständig geklärt, welche Parameter determinieren, ob
eine auto-reaktive T-Zelle durch Deletion beseitigt oder ob sie in eine regulatorische T-Zelle
umfunktioniert wird.
Um diesen Punkt näher zu untersuchen, entwickelten wir ein T-Zell-Rezeptor transgenes
Mausmodell (TCR-PLP1), welches ausschließlich T-Zellen hervorbringt, die das körpereigene
Antigen Myelin Proteolipid Protein (PLP) auf dem Haupthistokompatibilitätskomplex H-
2b der Klasse II erkennen können. PLP ist Hauptbestandteil der Neuronen umgebenden
Myelinscheide und von besonderem Interesse, da das körpereigene Antigen als Kandidat für
die Entwicklung Multipler Sklerose beim Menschen gilt. Es konnte gezeigt werden, dass eine
intrathymische Expression von PLP bereits ausreichend für die Induktion von zentraler Tol-
eranz ist [3]. Mit Hilfe des neu entwickelten TCR-PLP1 transgenen Mausmodells konnten
wir die Stellschrauben zentraler Toleranzinduktion gegenüber einem körpereigenen Antigen
untersuchen, welches im Thymus auf physiologischem Niveau exprimiert wird. Dabei fanden
wir, dass PLP-speziﬁsche T-Zellen im Thymus sowohl deletiert als auch in die regulatorische
T-Zellllinie umgeleitet werden, um Toleranz gegenüber PLP entstehen zu lassen. Sowohl die
Expression von PLP in thymischen medullären Epithelzellen (mTECs) als auch die Präsen-
tation des endogenen Antigens PLP durch diese Zellen vermittelt zentrale Toleranz auf
autonome Art und Weise. Thymische dendritische Zellen spielten bei der Entstehung von
Toleranz gegenüber PLP keine Rolle. Interessanterweise scheint der Autoimmun-Regulator
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AIRE von essentieller Bedeutung für die Toleranzinduktion gegenüber PLP zu sein. Ob-
wohl PLP kein typisch AIRE-abhäniges Antigen ist, kontrolliert AIRE die Expression von
PLP mRNA in mTEChi Zellen und reguliert womöglich dadurch die Toleranzinduktion.
Weiterhin ergaben sich Hinweise, dass zentrale Toleranz in einem deﬁnierten Zeitfenster
entsteht. Negative Selektion von TCR-PLP1+ CD4+ T-Zellen beginnt am Tag 3, während
regulatorische T-Zellen erst 1 Woche nach Geburt entstehen. Überraschenderweise konnten
wir zudem beobachten, dass in unserem Mausmodell zentrale Toleranz gegenüber PLP nur
bis zu einem Alter von 6 Wochen induziert wird und danach verloren geht. Eine Altersab-
hängigkeit wurde bisher für die Toleranzinduktion nicht genauer beschrieben und erweitert
dessen Komplexität um einen weiteren Aspekt.
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1 Introduction
The role of the immune system is to protect the organism from infectious agents and cancer.
It is a combination of two fronts: the fast acting innate immune system and the slower but
more speciﬁc adaptive immune system. When a pathogen inﬁltrates the ﬁrst defenses of
the body, innate immune mechanisms are brought into action. Defense mechanisms of the
innate immune system range from nonspeciﬁc chemical defense, such as the complement
system and antimicrobial peptides, to the recruitment of eﬀector cells, such as macrophages,
natural killer T (NKT) cells, mast cells, and granulocytes to quickly get rid of the pathogenic
threat. This system is rapid in action, but limited in the sense that it does not recognise
all foreign microbes and substances, especially pathogens that are modiﬁed over time.
The adaptive immune system has evolved to target pathogens in a more speciﬁc manner,
based on its ability to continuously adjust to novel antigenic challenges. This system consists
of two branches, (I) humoral immunity mediated by B lymphocytes and antibodies and (II)
cellular immunity mediated by CD4+ helper T lymphocytes and CD8+ eﬀector T lympho-
cytes. A hallmark of the adaptive immune system is (a) the immunological memory which
results in a faster and stronger immune response when the pathogens are re-encountered,
and (b) the vast diversity and speciﬁcity of the antigen receptors expressed on the surface
of lymphocytes.
1.1 Central tolerance
Immunological responses mediated by T cells are crucial for providing protective immunity
but depend on the acquired ability to discriminate between foreign and self. The T cell
receptor (TCR) is composed of two polypeptides () that contain variable regions and
recognise peptide-bound major histocompatibility complexes (MHC). To accomplish the
generation of a diversiﬁed repertoire of T lymphocytes that can eﬀectively respond to a
multitude of potential antigens, thymocytes are continuously generated de novo and un-
dergo random gene rearrangements at the TCR loci to produce a diﬀerent receptor for each
21
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cell. As the antigen-speciﬁc receptors of thymocytes are assembled through random somatic
DNA rearrangement, the emerging T cell pool inevitably includes TCR speciﬁcities reactive
to self-antigens. To avoid the potentially pathological state of autoimmunity, it is essential
to remove these self-reactive T cells from the repertoire, either by deletion or silencing.
Some T cell speciﬁcities are dismissed in the thymus soon after generation, because they do
not recognise peptides in context of self-MHC, which is one of the prerequisites of further T
cell development. For the remaining immature lymphocytes, central tolerance mechanisms
assure that they acquire the ability to distinguish between self and non-self, before they
are allowed to egress into the periphery. For an eﬀective central tolerance, T cells must
be challenged in the thymus with a complex array of diﬀerent peptides, which present pe-
ripheral self-antigens (ubiquitous and tissue-restricted) that the T cells may encounter at
any point in their lifetime in the periphery. The major mechanisms of central tolerance are
clonal deletion, inactivation, and diversion of self-reacting thymocytes into the regulatory
T cell lineage [4]. All these mechanisms occur in the thymus, whereas peripheral tolerance,
on the other hand, concerns mature lymphocytes after they have exited the thymus and
are circulating in the periphery. Mechanisms for peripheral tolerance also include clonal
deletion, anergy, and diversion, but a variety of additional mechanisms come into play,
including clonal ignorance and suppression of self-reactive lymphocytes [5–7].
Currently, the relative contributions of dendritic cells, thymic epithelial cells, and other
antigen-presenting cells in the thymus to the prevention of autoimmunity are poorly under-
stood [7–9].
1.2 Development of thymocytes
1.2.1 The thymus
T cells, diﬀerent to other hematopoietic cells, do not develop in the bone marrow but in the
thymus. The thymus is the primary lymphatic organ that provides a specialised microen-
vironment for T cell development. T cells develop in a strictly controlled spatiotemporal
manner along diﬀerent compartments of the thymus. In short, the thymic stroma cells
present certain signals to the arriving progenitors to commit to the T cell lineage, guiding
them to arrange their antigen receptor, and probe these for functionality and speciﬁcity to
self.
The thymus is compartmentalised into the outer, darker zone, the cortex, and the inner,
lighter zone, the medulla. The cortex is mainly comprised of cortical thymic epithelial
22
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cells (cTECs) and operates in positive selection, while the medulla has been shown to cru-
cially contribute to tolerance induction by expressing otherwise tissue-restricted antigens
(TRAs), thereby mirroring the peripheral self. During their guided journey through the
thymic compartments, T cells have to pass several checkpoints: Either they die or they
pass on to the next developmental stage until eventually being released into the periphery.
Selection processes in the thymus ensure that fully diﬀerentiated thymocytes fulﬁll two es-
sential prerequisites: ﬁrst, that they recognise and respond to foreign peptides presented
on self-MHC complexes, and second, that they are tolerant to self-peptides presented.
Three key events mark the developmental progression of these cells:
1. Positive selection
2. CD4/CD8 lineage diﬀerentiation
3. Negative selection
1.2.2 Developmental stages
Early T cell development is subdivided into four stages characterised by the cell surface
markers CD44 and CD25 and the location of the cell within the cortex [10] (see Fig. 1). The
most immature subset of thymocyte precursors (DN1) reside in the perimedullary cortex,
lack CD4 and CD8 expression and are characterised by the surface markers CD44+CD25-
[11]. Before DN1 cells develop further into the DN2 developmental stage in the inner cortex
(CD44+CD25+), they expand by proliferation about 1000-fold [12,13]. Further maturation
of cells coincides with migration into the outer cortical region and developmental progression
to the DN3 (CD44-CD25+) stage. Cells reside about 2 days in the subcapsular zone,
undergoing proliferative expansion and irreversible commitment to the T cell lineage [14].
1.2.3 Generation of the T cell receptor
A key process of the development of thymocytes is the generation of a T cell receptor
(TCR), which also takes place in the cortex. Recombination events start at the DN3 stage
and critically depend on the expression of the recombination activation genes (RAG1 and
RAG2), presumably regulated by signalling of IL-7 [15]. The RAG genes help to recombine
the germ line encoded VDJ segments of the TCR locus in two steps [16,17]:
First, rearrangement of the DJ genes take place on both alleles and then, subsequently,
the recombined DJ segments rearrange with the V segment forming the TCR chain. Pro-
ductive rearrangement of the TCR chain gene on one chromosome, prevents further gene
23
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Figure 1: Schematic view of the early stages of thymocyte development. The hematopoietic T
cell precursors enter the thymus at the cortico-medullary junction and migrate towards the outer cortex.
During that period, the precursors commit to the T cell lineage and undergo several diﬀerentiation steps
characterised by diﬀerential expression of the surface markers CD44 and CD25. During this diﬀerentiation,
the lymphocytes do not express CD4 nor CD8 and are referred to as double negative cells, namely DN1
to DN4. At the DN3 stage, thymocytes start to rearrange their TCR locus, which will be coupled to
a pre-TCR chain in order to test the rearrangement for functionality. When the -selection is positive,
the TCR loci will also start to rearrange and simultaneously upregulate the expression of the co-receptors
CD4 and CD8 (DP). Positive selection by cTECs allows only those thymocytes to progress to the medulla,
which have rearranged a functional TCR. During positive selection, thymocytes commit to either the CD4
or the CD8 T cell lineage, depending on the MHC type their TCR is selected by. Positively selected CD4SP
or CD8SP thymocytes, will then progress to the medulla, where they are screened for reactivity towards
self-antigens, a process called negative selection.
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rearrangements at the second TCR allele, a process termed “allelic exclusion” [18–20].
This stage marks the ﬁrst checkpoint during T cell development and is called -selection.
The newly formed TCR chain forms a heterodimer with an invariant pre-TCR chain,
CD3d, and this pre-TCR is tested for functionality [21,22]. Only those T cells that express
a fully functional pre-TCR on their surface receive a survival signal and are permitted to
progress to the next developmental stage, the CD4/CD8 double positive (DP) stage and
will be positively selected [21, 22]. The transition from CD4/CD8 double negative (DN)
to double positive (DP) immature T cells is referred to as the fourth stage of early T cell
development, the DN4 or pre-DP stage (CD44-CD25- CD4lowCD8low), and is accompanied
by the migration to the outermost cortex, marking an irreversible commitment to the T cell
lineage [14,23]. At the transition from the DN stage to the DP stage, the precursor pool is
heavily proliferating in order to guarantee a large pool of cells carrying functional -chains
that can later independently rearrange their -locus. This will help to enrich the diversity
of the TCR T cell repertoire [24,25]. During the whole expansion phase, the RAG genes
are turned oﬀ to prevent premature rearrangements of the TCR locus, which start when
the pre-DP cells arrive at the subcapsular zone.
1.3 Positive selection
While the recombination of the TCR locus is still ongoing, the cells upregulate the co-
receptors CD4 and CD8 and are challenged with the next checkpoint, positive selection
[23]. Positive selection is characterised by interactions between the DP T cells and cortical
epithelial cells. Only those T cells carrying a functional T cell receptor that recognises
peptides in the context of self-MHC molecules well enough for functional signal transduction
are positively selected. This phenomenon is called “recognition of self” and ensures that
the randomly generated repertoire is useful to the host, as it is able to recognise peptides
presented on self-MHC complexes [26–28]. At this stage, DP T cells can continuously
rearrange their TCR chain until they are positively selected [29]. Further rearrangement
of the second TCR locus occurs when the ﬁrst receptor combination is not able to interact
with thymic self-MHC molecules [30,31]. As allelic exclusion is not as tightly controlled at
the TCR locus, it is possible that some T cells can express two  chains paired with a
common TCR chain on the cell surface [32–34].
The binding strength of the interaction between TCR and peptide-loaded MHC complex
(pMHC) on cTECs is a critical parameter for survival: If the aﬃnity is “high enough”,
the T cell will receive a TCR stimulus that leads to downstream expression of survival
molecules allowing further progression to the medulla for negative selection [35]. If the
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TCR shows “no” or “low ability” to bind to peptide-MHC complexes, the cell does not
receive these survival signals and will undergo apoptosis, a process called “death by neglect”
[28,36]. Positive selection is a crucial step that enriches for T cell progenitors that are MHC
restricted. This step, of course, also enriches for self-reactive cells, thereby requiring the
indispensable necessity of negative selection processes in the medulla.
1.4 CD4/CD8 lineage choice.
During positive selection, T cells express both CD4 and CD8 co-receptors. This allows a sur-
vival of as many thymocytes as possible in the positive selection process. The next important
step immediately following the selection of successfully rearranged and self-restricted TCRs,
is the CD4/CD8 lineage choice. Exact modalities for lineage choice are still under debate.
Yet, it is widely accepted that DP thymocytes that have been positively selected become
CD4+ CD8low intermediate cells, that are still lineage-uncommitted but have the potential
to diﬀerentiate into either CD4 single positive (CD4SP) or CD8 single positive (CD8SP)
thymocytes [37, 38]. Depending on whether the selected cell has a MHCI- or a MHCII-
restricted TCR, it will develop into a CD8SP or CD4SP thymocyte, respectively [39–41].
1.5 Negative selection
The process of negative selection is often considered as the third and last critical checkpoint
during T cell development. Tolerance in the medulla is established in two ways: recessive
tolerance (clonal deletion) and dominant tolerance (the development of regulatory T cells).
Both types of tolerance are thymus-dependent processes, based on high-aﬃnity interactions
between TCR and peptide-MHC but with two diﬀerent outcomes for a thymocyte involved
in TCR assessment [42].
Subsequent to positive selection and CD4/CD8 lineage commitment, thymocytes translo-
cate to the medulla, where they reside for 4 5 days before receiving their “exit permit” [43].
Mice with mutations helped to identify the medulla as the place for negative selection as
a disorganised or even an absent medullary structure led to severe autoimmunity but un-
altered positive selection this these mice [44–47]. Also, mice deﬁcient for the chemokine
receptor CCR7, which is important for migration of T cells to the medulla, develop autoim-
mune pathology [48].
In the medulla, thymocytes with strong reactivity to presented self-antigens will be re-
moved in order to ensure a self-tolerant T cell pool that is of no potential harm to the
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organism [49,50]. It is a coordinated process that depends on the interaction between thy-
mocytes and the major antigen-presenting cell types in the medulla. The two best described
antigen-presenting cell types involved in the medulla in negative selection are the thymic
dendritic cells (thymic DCs) and the medullary thymic epithelial cells (mTECs) [50–52].
These cells both express higher levels of MHC molecules and in contrast to cTECs, also the
co-stimulatory molecules CD40, CD80, and CD86, important for negative selection [53–56].
Recently also B cells were reported to play a role in negative selection, but their full con-
tribution is still be found out [57,58].
Thymic dendritic cells (thymic DCs). Thymic DCs in the medulla consist of an
autochthonous DC population and DCs that arise extra-thymically. The DC population of
intra-thymic origin is mostly composed of SIRP- (signal regulatory protein alpha-negative)
CD11b- CD8hi cells [59, 60]. The migratory DC population that originated outside the
thymus consists of immature plasmacytoid DCs (pDCs) and the SIRP+ CD11b+ CD8-
subset of conventional DCs (cDCs) [60]. Both migratory DC subtypes can take up and
transport circulating antigen to the thymus [61].
Thymic medullary epithelial cells (mTECs). mTECs are unique among thymic
antigen-presenting cells (APCs) in that they express an immense number of otherwise tissue-
restricted antigens (TRAs) [1, 51, 62]. The mTEC population is mainly composed of two
subpopulations: the MHCIIlow AIRE- immature, proliferating population (mTEClo), and
the MHCIIhigh CD80high mature population (mTEChi), which divides further into cells pos-
itive or negative for the expression of the autoimmune regulator gene (AIRE) [63–65] (for
AIRE see section 1.7) .
Interactions of developing T cells with peptide-MHC complexes on medullary APCs as
quality control are indispensable for central tolerance. For negative selection to be produc-
tive, self-antigens must be presented as peptide-MHC complexes to developing thymocytes.
If the thymocytes react with presented self-antigens too strongly, they are thought to be
negatively selected, while if they recognise self-antigens with low aﬃnity, they are allowed
to undergo further development. Negative selection of T cells is induced by several mech-
anisms: Deletion, anergy, and receptor editing. Clonal deletion is the suicide of T cell
progenitors that have high aﬃnity for self-antigens, and is considered the hallmark of cen-
tral tolerance induction [52]. The other processes (anergy and receptor editing) also impair
or eliminate high-aﬃnity self-reactive cells but are thought to play a lesser role.
However, even in healthy individuals negative selection is inevitably incomplete, leading to
the emergence of T cells that potentially react against “self”. Therefore, there are several
additional regulatory mechanisms beyond negative selection to enforce self-tolerance. One
of these is the development of regulatory T cells (Treg cells), a process that is strongly
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related to negative selection [66]. Treg cells that arise in the thymus and are not induced in
the periphery are termed “natural Tregs” (nTregs) [67]. FOXP3 (forkhead box protein 3) is
currently seen as the master regulator of this regulatory T cell lineage and a major marker
of this population [68–71]. Direct evidence for the importance of nTregs comes from experi-
ments showing that depletion of Foxp3+ Treg cells in neonatal mice caused the development
of autoimmune disease, which could be cured by the re-introduction of Treg cells [72]. Also,
mice with a mutated Foxp3 gene (scurfy mice) develop lethal autoimmunity [73].
Work with the TCR-HA x AIRE-HA mouse model, in which TCR-transgenic T cells recog-
nised their cognate antigen HA on mTECs, provided some crucial evidence that the gener-
ation of Tregs is based on self-recognition in the thymic medulla and occurs with negative
selection [74, 75]. It is now widely accepted that “natural” Foxp3+ CD25+ regulatory T
cells originate in the thymus and are the best characterised mediators of dominant tolerance
so far [67,76]. Utilising AIRE-driven CIITA knockdown (C2TAkd), to lower the expression
of a cognate antigen on MHCII molecules in the medulla, it could be shown that reduced
quantity of presented antigen decreased negative selection and fueled Treg development for
several tested TCR speciﬁcities [77]. This data argued that the instructive phase of Treg
development is rather based on the avidity of TCR/peptide-MHC interactions than on the
aﬃnity of the TCR interactions.
Thus, not all central tolerance mechanisms cripple self-reactive T cells. The positive se-
lection of regulatory T cell populations in the thymus enables T cells to actively suppress
immune responses to structures of self that are recognised in the periphery [52].
1.6 Promiscuous gene expression
While it was easy to understand, how tolerance to ubiquitously expressed or blood-borne
antigens is tested and maintained in the thymus, it was far more diﬃcult to understand
how thymocytes that are reactive to proteins expressed only in non-thymic parenchymal
tissues were tolerised. This was revealed when several studies reported that otherwise tissue-
restricted antigens (TRAs) were being ectopically expressed by mTECs in the thymus [1,2].
This so-called promiscuous gene expression (pGE) identiﬁed the basis for tolerance induc-
tion to a broad array of antigens found in the whole body [78–80]. Strikingly, TRAs were
being ectopically expressed despite the tightly controlled lineage-speciﬁc gene expression.
By pGE, the thymus comprehensively mirrors the immunological self of peripheral tissues
and is able to maintain tolerance [2].
Because the expression of a given tissue-restricted antigen is restricted to a very small
number of thymic APCs, the proper presentation of such a rare antigen is of critical impor-
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tance [1,80]. It is desirable that all thymocytes are exposed to all TRAs during their stay in
the medulla, each expressed by a minute number of mTECs, before exiting into the periph-
ery. In order to enlarge the scope of antigen presentation, it was found that mTEC-borne
peptides were spread in the thymic medulla uni-directionally from mTECs to neighbouring
thymic dendritic cells [80–82]. For presentation of mTEC-derived self antigens by DCs, the
peptides may be directly transferred to DCs or involve an intercellular transfer of an entire
functional pMHC molecule and other TEC-speciﬁc membrane proteins [83,84]. Diﬀerences
in the quality of tolerance induction when directly or indirectly presented are only slowly
emerging and are still under debate. While there is evidence that the direct presentation of
antigens by mTECs is suﬃcient for tolerance induction [77, 80, 85], it has been shown that
some antigens require the transfer to DCs for eﬃcient presentation [86]. Further studies
are needed to delineate the impact of indirect vs direct presentation of TRAs.
1.7 AIRE
The importance of the expression of TRAs in the thymus has been emphasised by the
study of the rare human immune disorder autoimmune-polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED), which is characterised by a spectrum of autoimmune
diseases caused by mutations in the Autoimmune regulator (AIRE) gene [87–89]. The
generation of AIRE-deﬁcient mice was instrumental in identifying the cellular role of AIRE
and it became apparent that AIRE is directly linked to central tolerance. Deﬁciency in the
expression of AIRE led to the development of multi-organ autoimmunity with inﬂamma-
tory inﬁltrates and autoantibody production, thus recapitulating the pattern of the disease
APECED [2,5, 89].
The nuclear protein AIRE has a role in promiscuous gene expression of otherwise tissue-
restricted antigens [90]. The encoded AIRE protein is expressed primarily in mature
medullary thymic epithelial cells (mTEChi) in the thymus [1, 2]. AIRE is also expressed
in peripheral lymphoid tissues, where its contribution to tolerance is only starting to be
unraveled [91]. Analysis of AIRE-deﬁcient mTECs revealed that expression of some but not
all TRAs are regulated by AIRE [2, 62, 92–94]. Although the precise molecular mechanism
of AIRE is still largely obscure, its functional domains and several interacting partners
have been identiﬁed. At ﬁrst glance, AIRE appears to be a classical transcription factor,
however, several ﬁndings hint at a broader function of AIRE. Abramson et al. [95] showed
that AIRE interacts with an unexpectedly large number of binding partners: proteins that
are involved in RNA processing, transcription, nuclear transport, DNA damage response,
and proteins for chromatin binding and chromatin structure. It was further reported that
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AIRE preferentially binds to the unmethylated histone H3 at lysine-4 (H3K4me0), a marker
for inactive regions [96]. This indicates that AIRE could function as a transcriptional acti-
vator to initiate expression of target genes. Additionally, the interaction of AIRE with the
transcriptional co-activator Creb-binding protein and the positive transcription elongation
factor b also implies enhancement of gene expression mediated by AIRE [97, 98]. Current
models posit that AIRE acts at the chromatin opening, and there, recruits the positive
transcription elongation factor b to inactive genes at which arrested RNA polymerase II is
already present, leading to noisy gene expression in mTECs [65,99,100].
AIRE regulates the expression of many TRAs, but not all [62]. There are also TRAs that
are expressed independently from AIRE and may be produced by a distinct subclass of
mTECs [64]. It was proposed that some of the AIRE-independent TRAs might be regulated
by the LTR signalling pathway [101]. However, it seems more likely that the autoimmune
phenotype in LTR-deﬁcient mice was caused by the disorganised medullary structure,
restraining thymocytes from interacting properly with medullary APCs [93]. Moreover, it
was suggested that a subset of TRAs ﬁrst seemingly dependent on AIRE, might be regulated
indirectly by AIRE. As Anderson et al. [2] showed that AIRE activates the expression
of several transcription factors, these might subsequently mediate the expression of many
apparently “AIRE-dependent” TRAs. Thus, the pool of AIRE-dependent antigens might be
further enhanced by adding these secondary targets to the direct primary targets [102]. Also,
AIRE expression was thought to be proapoptotic, enhancing mTEC death, and therefore,
intensifying antigen-spreading to DCs for cross-presentation [5, 103].
It was later found that AIRE might possess even more functions than purely controlling the
expression of TRAs. Additionally, it was proposed that AIRE is involved in the regulation
of antigen processing and presentation, mTEC diﬀerentiation and thymocyte migration
[63, 90, 104–106]. AireKO mice were reported to show a disorganised medullary structure
with fewer thymic DCs in the medulla [103, 106–108], and delayed migration leading to
reduced thymic egress in the early phase after birth [109]. Thus, AIRE-deﬁciency obviously
aﬀects other aspects involved in central tolerance. The contribution of each AIRE-related
mechanism in respect to mediating negative selection and Treg induction still needs to be
fully unraveled.
1.8 T cell receptor-transgenic animals
T cell receptor (TCR)-transgenic mice have been established as powerful tools in the eluci-
dation of various aspects of central tolerance as well as T cell development. TCR-transgenic
animals are generated by the introduction of productively rearranged TCR cDNA into the
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genome, and therefore, TCR-transgenic mouse models can be used as a source of naive, al-
most pure mono-speciﬁc T cells. Since sucessfully rearranged T cell receptor chains largely
prevent the further rearrangement of TCR loci, the transgene-encoded receptors are subse-
quently present on the majority of T cells [20]. This made it possible to track the behaviour
and fate of T cells with deﬁned speciﬁcities. This method was ﬁrst accomplished with
the generation of the HY-transgenic mouse that enabled the study of negative selection in
vivo [110]. More TCR-transgenic mice followed, providing tools to analyse positive selection
and the role of altered peptide ligands in establishing the kinetic signalling model [111,112].
With the help of TCR-transgenic mouse models expressing a receptor for a self-antigen
along with the self-antigen, it was also possible to address questions of central tolerance.
These mice provided an excellent tool for studying negative selection, the relevant APC for
central tolerance induction, and the molecular signalling events involved. In most of these
systems, the genes for model antigens, such as ovalbumin [113] or hen-egg lysozyme [114],
are not a natural part of the mouse genome and were rather transgenically introduced. It
is clear that the nature of the TCR and of the model antigen (its structure, its localisation,
its dose, and the time during which the antigen is available) are all important factors and
can have major impacts on the timing and the mechanism by which speciﬁc T cells are
tolerised [43, 115]. It is therefore important to make use of the most physiological tools
possible to avoid studying artefacts.
It has long been quite unclear which ﬂanking sequences exactly are required for proper
TCR expression and often heterologous promoter fragments have been used to drive TCR
expression. Some combinations have sometimes led to an abnormal timing and regula-
tion of expression of the TCR genes. For this reason, the laboratory of Mathis & Benoist
further elaborated TCR cassette vectors, originating from the HY-speciﬁc TCR-transgenic
mice that carried all essential promoter and enhancer elements for TCR expression [116].
These newly engineered TCR cassette vectors include the natural, TCR-derived regulatory
elements and only short segments of rearranged  and  variable regions need to be intro-
duced. These pT and pT cassette vectors are now widely used and were also used for
the generation of the TCR-PLP1 transgenic mouse described in this thesis.
However, TCR heterodimers of TCR-transgenic mice are expressed still earlier in devel-
opment than naturally arising TCRs that have been subject to somatic gene rearrangements
(Fig. 2). This could have potential implications for the positive and/or negative selection
of the TCR and need to be carefully monitored.
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Figure 2: The timing of T cell receptor arrangements in TCR-transgenic mice compared to
normal mice. Schematically steps of T cell developmental stages for rearrangement of the TCR in normal
mice compared to the early expression of the TCR in TCR-transgenic mice. In TCR-transgenic mice, the
TCR is mostly expressed by the DN2 stage. A) In normal T cell development, thymocytes start to rearrange
their TCR locus at the DN3 stage forming a pre-TCR with the arranged -chain. Only at the pre-DN4/DP
stage, an intact TCR heterodimer is produced and brought to the cell surface. B) In TCR-transgenic
mice, in contrast, both chains of the TCR heterodimer are expressed early in development typically at
the DN2 stage. Figure from Hogquist et al. (2005) [52].
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1.9 Myelin proteolipid protein (PLP)
Myelin is a specialised membrane found exclusively in the nervous system of vertebrates. It
is wrapped around the nerve axon and acts as an insulator allowing nerve impulses to pass
quickly along the axons by saltatory conduction between the nodes of Ranvier (see Fig. 3 A).
Furthermore, it provides stablility, support to the axon, and maintains its integrity. Myelin
is composed of lipids and associated membrane proteins. The three main myelin proteins
are myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligoglycoprotein
(MOG). Myelin is present in both the central nervous system (CNS), where it is produced
by oligodendrocytes, and in the peripheral nervous system (PNS), where it is produced by
Schwann cells. In the CNS, more than half of the protein found in the myelin sheath is
proteolipid protein (PLP) [117]. In the PNS, PLP is present at very low concentrations in
Schwann cells, but is not inserted into the PNS myelin membrane [118–121].
PLP is an integral membrane protein with four hydrophobic -helices as transmembrane
domains [122, 123] and is encoded on the X-chromosome (see Fig. 3 B). PLP also exists
as isoform DM20 that is generated by alternative mRNA splicing [124]. It diﬀers from
full-length PLP by a deletion of an intracellular loop of 35 amino acids but shares the over-
all ’four-helix-span’ topology [125, 126]. It was reported that PLP plays a critical role in
oligodendrocyte diﬀerentation and survival [127]. Across species, PLP enjoys a strong con-
servation in its amino acid sequence [121,128–131] underlining its important role in forming
myelin sheaths. For this reason, it is possible to use bovine PLP for the induction of murine
experimental autoimmune encephalomyelitis (EAE), a murine model disease for the human
Multiple Sclerosis.
Substitution or mutations of even single amino acids that lead to a conformational change
of PLP, renders PLP incapable of being brought to the cell surface, interfering with oligo-
dendrocyte diﬀerentiation and survival [127, 132]. PLP deﬁcient mice have been generated
by the introduction of the neomycin resistance gene in exon 1 of the genomic sequence of
PLP, resulting in a complete loss of expression for both PLP forms, PLP-full length and the
DM20 isoform [133]. Surprisingly, these mice do not suﬀer from abnormal motor develop-
ment nor the classical demyelination phenotype, and only develop neurological impairments
at the age of 16 months [133,134].
1.9.1 Experimental autoimmune encepahlomyelitis (EAE)
Experimental autoimmune encepahlomyelitis (EAE) is the murine model disease forMultiple
sclerosis. Multiple sclerosis (MS) is a chronic disorder characterised by the inﬂammation of
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B
Figure 3: Structure of myelin in the nervous system and the transmembrane protein proteolipid
protein (PLP). A) Myelin is an insulating membrane wrapped around axons of the nervous system. It
allows nerve impulses to pass quickly along the axons by saltatory conduction between the nodes of Ranvier.
In the CNS, more than 50% of all proteins in the myelin sheath are proteolipid proteins (PLP). Illustration
from http://multiple-sclerosis-research.blogspot.com/2013/01/imaging-myelin.html. B) The protein PLP is
depicted schematically with its amino-acid sequence. It is an integral membrane protein with four -helices
spanning the membrane. The position of PLP9-20 is highlighted in red. The deleted stretch of 35 amino
acids in the DM20 isoform is indicated with green circles. Illustration adapted from Greer (2013) [118].
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the white matter in the central nerve system. The hallmark of the disease is the demyelina-
tion of nerve ﬁbers, which then leads to axonal injury, neurological deﬁcits and progressive
physical impairment [135]. The precise course of the disease and especially its activation
is not yet fully understood. However, it is widely believed that MS is initiated by the in-
ﬁltration of autoreactive T cells into the CNS and the subsequent immune attack on CNS
myelin [136]. Yet in MS, the group of auto-antigens responsible for disease initiation is very
heterogeneous [137]. MS is a highly prevalent disease with an estimated incident rate of 1
in 500 in Europe [138].
“Classic EAE” in mice is characterised by ascending paralysis beginning at the tail, followed
by hind limb paralysis and forelimb paralysis and is assessed semi-quantitatively using a
5-point scale (see also methods for scale 5 [139]). Upon induction of EAE, inﬂammatory
cells inﬁltrate the CNS, release inﬂammatory mediators that will cause inﬂammation and
subsequent tissue destruction, resulting in paralysis of the animal. The nature of the as-
cending paralysis is due to the fact that the cells begin to inﬁltrate the CNS in the lumbar
region of the spinal cord. The disease progresses in severity as more of the spinal cord be-
comes inﬂamed and shares clinical and histopathological similarities to the human Multiple
sclerosis [117,140].
1.9.2 Central tolerance to PLP
As Multiple Sclerosis is a very severe autoimmune disorder, tolerance mechanisms should
ensure the absence of myelin-speciﬁc T cells in the organism and PLP has been implicated
in the etiology of MS in humans. To tolerise the T cell pool to PLP, the expression of the
antigen in the thymus is required. The DM20 form is preferentially expressed in the thymus
and secondary lymphoid organs, while the full-length PLP is predominantly expressed in
the brain itself [141]. Susceptibility to EAE induction by immunisation with proteins of the
CNS depends greatly on the genetic background of the mouse and MHC. In SJL/J mice
(H-2s), immunisation with protein including the immunodominant epitope of this haplotype
PLP139-151 leads to the induction of EAE. Immunisation with the same protein/peptide in
C57BL/6 mice (short: B6; H-2b) is without consequences [142, 143] and states the strong
tolerance to PLP in this strain. While the B6 strain shows a high resistance to PLP-induced
EAE, it can be induced by immunisation with MOG that eventually results in a chronic
form of EAE [142,144]. Klein et al. [3] showed with transplantation experiments in PLP-/-
animals that the intra-thymic expression of PLP is suﬃcient for tolerance induction.
The full spectrum of dominant and subdominant immunogenic epitopes of PLP on the
B6 background has been identiﬁed. Klein et al. immunised B6 WT and B6 PLP-/- mice
with PLP protein and subsequently re-stimulated the primed lymph node T cells with
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Figure 4: The four immunogenic regions of the PLP protein in the context of H-2b. Four
immunodominant regions in the context of H-2b could be identiﬁed by recall analysis of immunised B6
PLP-/- mice in comparison to B6 WT animals. Reactivities against peptides PLP160-184/PLP176-200 and
PLP224-248/PLP240-264 represented overlapping epitopes (marked with a black diamond). Responses to the
peptides PLP1-24 and PLP192-216 represent individual epitopes. In B6 wild-type mice (B6 PLP+/+), the
response to these epitopes was virtually absent. Only a residual reponse to the peptide PLP160-184 was
detected. Figure adapted from Klein et al. (2000) [3].
sets of overlapping peptides (25 amino-acids in length), spanning the entire sequence of
the protein PLP with a shift of 16 amino-acid residues. Speciﬁc recall responses to these
peptides, revealed four immuno-relevant regions of PLP in the context of H-2b (Fig. 4). By
reduction of the peptide length for restimulation from 24 amino acids to 12 amino acids,
it was possible to single out four core-epitopes in the B6 genetic background: PLP11-18,
PLP174-181, PLP205-213, and PLP240-247. These achievements set the basis for delineating
central tolerance mechanisms to the self-antigen PLP in the following work.
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With this study, we contribute to understanding central tolerance induction to a tissue-
restricted self-antigen of the central nervous system. Speciﬁcally, we study the modalities
of thymic tolerance induction to the self-antigen myelin proteolipid protein (PLP), a native
self-antigen whose intra-thymic expression was shown to be suﬃcient to mediate toler-
ance [3].
PLP is one of the major components of the CNS and is considered as candidate antigen
in the etiology of the human autoimmune disease Multiple Sclerosis [145, 146]. Therefore,
functional tolerance induction to PLP is crucial to prevent the development of disease. Also
in mice, it was possible to elicit the corresponding disease, experimental autoimmune en-
cephalomyelitis (EAE) by immunisation with PLP protein, yet the severity of the disease
depended greatly on the genetic background [117]. While SJL mice, for instance, were
highly susceptible to EAE induction by immunisation, the C57BL/6 (B6) mouse strain was
strongly resistant to disease development [142]. In B6 mice, the immunogenic regions of
PLP in the context of H-2b were already identiﬁed [3] (see also Fig. 4). The core epitopes
were namely: PLP11-18, PLP174-181, PLP205-213, and PLP240-247.
We wanted to elucidate central tolerance mechanisms in a physiological setting. Therefore,
we chose to study central tolerance induction to the naturally occuring, physiological rel-
evant self-antigen PLP. Since it is diﬃcult to trace individual T cells speciﬁc for PLP in
a polyclonal system, we generated a PLP-speciﬁc TCR-transgenic mouse. Here, we could
monitor thymic selection of a single TCR speciﬁcity due to the dominant expression of this
genetically introduced T cell receptor. It is the ﬁrst PLP-speciﬁc TCR-transgenic mouse
model in the B6 background. While there has been a TCR-transgenic mouse model in
the B6 background generated for MOG35-55 (2D2 mice) [147], PLP-speciﬁc TCR-transgenic
mice have only been generated in the SJL/J background [148], and only for the region
PLP139-151 (5B6 and 4E3) [148], which is immunodominant in this genetic background. For
the B6 background, we focused on the immunogenic epitope PLP11-18, as tolerance induc-
tion to this epitope was very eﬃcient. With the generation of the TCR-PLP1 transgenic
mouse, we were able to trace the fate of PLP-speciﬁc T cells in a thymus with strong tol-
erance mechanisms to PLP. Furthermore, by crossing the TCR-PLP1 transgenic mouse to
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other mouse strains with deﬁciencies in the expression or presentation capacity of PLP, we
were able to delineate the roles and contributions of the diﬀerent thymic APC subsets for
tolerance induction to the antigen PLP.
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3.1 B6 WT mice show a robust tolerance to PLP
As a starting point, we wanted to recapitulate the tolerogenic response to all four identiﬁed
immunogenic epitopes in the B6 genetic background that have been published in Klein et
al. [3] (see also Fig. 4). To this end, WT or PLP-/- mice were immunised with PLP protein
and 9 days later, the draining lymph node cells were isolated and in vitro restimulated with
four diﬀerent peptides (24-amino acids in length) spanning the identiﬁed immunogenic
epitopes respectively: peptide PLP1-24 for the core epitope PLP11-18, PLP160-184 for the
core epitope PLP174-181, PLP192-216 for the core epitope PLP205-213, and lastly PLP224-248
for the core epitope PLP240-247.
Immunisation of PLP-/- mice showed a primary T cell response to three of the four identiﬁed
epitopes (Fig. 5). While we detected a stimulation response similar in strength to the
peptides PLP1-24, PLP160-184, and PLP224-248, the response to the peptide PLP192-216 was
absent or if at all only marginally detectable. In the published pep-scan by Klein et al. [3],
recall response to the 24-mer peptide PLP192-216 was also only little over background. In WT
mice, only the peptide PLP160-184 elicited a weak, but signiﬁcant recall response of primed
lymphocytes. Recall responses to the other peptides were absent in B6 WT mice. Thus,
B6 WT mice showed a robust tolerance to PLP, with exception of the peptide PLP160-184.
Our data is consistent with the reported observation that tolerance to this epitope was
not stringent in B6 WT mice, while tolerance to the other regions of PLP was tightly
regulated [3].
The aim of this thesis was to delineate the mechanisms of tolerance induction to the self-
antigen PLP in the thymus. As stimulation with the peptide PLP1-24 after immunisation
yielded the strongest recall response in PLP-/- mice, but showed a very strict tolerance in B6
WT mice, we focused on the immunogenic region PLP1-24, i.e. the core epitope PLP11-18,
for the generation of a PLP-speciﬁc TCR-transgenic mouse.
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Figure 5: Recall response to four PLP peptides after immunisation with PLP protein. In vitro
restimulation of draining lymph node cells with titrated concentrations of PLP peptide after immunisation
with 50 g PLP protein. A) Stimulation with PLP1-24 peptide, B) Stimulation with PLP160-184 peptide,
C) Stimulation with PLP192-216 peptide, and D) Stimulation with PLP224-248 peptide. In PLP-/- mice,
recall responses to the identiﬁed immunogenic regions of the PLP protein in the context of H-2b PLP1-24,
PLP160-184, and PLP224-248 were observed. The response to the peptide PLP192-216 was only marginally
over background. WT mice showed robust tolerance to all PLP peptides with the exception of the region
PLP160-184 (B). Stimulation with this peptides yielded also a recall response in B6 WT mice. Plotted is the
mean average (WT: n=3; PLP-/-: n=3) with the standard error of the mean (SEM).
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3.1 B6 WT mice show a robust tolerance to PLP
Immunisation with PLP protein and PLP1-24 peptide yielded the same recall
response
PLP is highly conserved between species [121,128–131]. As PLP protein is not commercially
available, it needs to be puriﬁed from brain extract and we used puriﬁed PLP protein extract
from cows for our research [117]. As we had access to only a limited amount of protein,
we needed to establish that the recall response of PLP-speciﬁc T cells after immunisation
with a synthetic PLP peptide spanning the relevant core epitope PLP11-18, elicited the same
recall response as immunisation with the whole PLP protein.
We compared immunisation with PLP protein with immunisation using PLP1-24 peptide
and detected by both approaches pronounced proliferation of lymphocytes originating from
PLP-/- but not from WT mice (Fig. 6). Both peptides used for the recall response (PLP1-24
after immunisation with PLP protein and PLP9-20 after immunisation ith PLP1-24) span
the immunogenic core epitope PLP11-18 that was previously identiﬁed by ﬁne-mapping
[3]. Immunisation with PLP1-24 peptide (Fig. 6 B) yielded a comparable recall response
measured by in vitro proliferation as immunisation with PLP protein (Fig. 6 A). For this
reason, we have performed all following immunisations with the 24-mer peptide PLP1-24.
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Figure 6: Comparison between immunisation approach with PLP protein and PLP1-24 peptide.
In vitro recall response of lymphocytes of the draining lymph nodes of PLP-/- and WT animals after
immunisation. A) Restimulation with PLP1-24 peptide after immunisation with PLP protein (n=3 mice
each); B) Restimulation with 12-mer PLP9-20 peptide after immunisation with 24-mer PLP1-24 peptide.
Immunisation with PLP1-24 peptide yielded comparable recall response in a subsequent in vitro stimulation
as immunisation with PLP protein. (PLP-/- n=8; WT n=3). Plotted is the mean average of the responses
with the standard error of the mean (SEM).
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3.2 Generation of the PLP9-20-speciﬁc TCR-transgenic
mouse
To study central tolerance to PLP, we aimed to generate a TCR-transgenic mouse spe-
ciﬁc for the core epitope PLP11-18. The basis of our PLP-speciﬁc TCR-transgenic mouse
(TCR-PLP1) is the transgenic introduction of a rearranged TCR sequence that gives rise
to T cells with high speciﬁcity towards the peptide PLP9-20, which spans the core epitope
PLP11-18.
In order to obtain a TCR speciﬁc for PLP9-20, PLP-/- mice were immunised with the 24-mer
peptide PLP1-24, which yields an expansion of T cells reactive to PLP1-24. 9 days later,
T cells were isolated from the draining lymph nodes and subsequently stimulated with the
12-mer PLP9-20 peptide in vitro, which further enriched T cells with speciﬁcity towards
this more restricted peptide, that spans the core epitope PLP11-18. After 1 restimulation
in vitro, we fused reactive T cells to the TCR-negative lymphoma reporter cell line
BW-NFAT-GFP in order to generate T cell hybridomas. T cell hybridomas are a combi-
nation of the reactive T cells and BW5147 cells, which are a thymoma cell line that lacks
inherent functional TCR chains. This step was conducted for the sake of easier handling
and screening procedures and allowed us to further characterise the T cell hybridomas by
staining for TCR V and V chains as well as assessing their reactivity to PLP. The early
fusion impeded the generation of an in vitro false bias but provided a broad panel of reactive
T cells for further testing.
Dominant use of the TCR variable region V6 in PLP9-20-speciﬁc T cells
In order to select for a representative TCR for the generation of the TCR-transgenic mouse,
we ﬁrst wanted to evaluate if PLP9-20-reactive T cells use a dominant TCR variable V
and V region. The basis for the generation of the TCR-transgenic mouse was to choose a
speciﬁc T cell clone that represented T cells that were responsive to the antigen PLP9-20. In
order to select for a T cell clone with a TCR that was dominant in its response to PLP9-20,
we compared the distribution of TCR variable V and V regions before and after immuni-
sation and after in vitro restimulation with PLP9-20. During the rearrangements of the TCR
loci, numerous variable TCR segments can be recombined with other gene segments: With
regards to the variable TCR regions, the TCR locus consists of 70-80 V gene segments,
while the TCR locus has “only” 52 functional V gene segments [149]. Antibodies for ﬂow
cytometry analysis do not exist for all TCR variable regions, therefore, we could compare
only the distribution of the TCR variable regions with antibodies available: 4 antibodies
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Figure 7: Screen of the distribution of TCR variable V and V regions within the CD4SP
compartment of lymphocytes before and after immunisation with PLP. Comparison of the TCR
variable V and V regions in T cells after repetitive stimulation with PLP9-20 peptide to T cell pools that
were either not immunised or not yet in vitro restimulated. After several rounds of stimulation with PLP9-20
peptide, an enrichment in T cells expressing a TCR variable region V6 was observed. WT not immunised:
n=16, PLP-/- not immunised: n=3, PLP-/- immunised d0 and after 2   3 rounds of stimulation: n=10.
Depicted is the mean average with the standard error of the mean (SEM).
for variable TCR genes, and 14 antibodies for diﬀerent variable TCR genes. A few res-
timulations with PLP9-20 peptide were suﬃcient to show an enrichment of T cells using the
TCR variable region V6 compared to the T cell pool that was unimmunised or not yet in
vitro stimulated (Fig. 7). Also an increase in the presence of TCR variable region V3 was
observed, but not as high as the level of V6. For the TCR variable -chains, we could not
detect a dominant chain in the T cell repertoire stimulated with PLP9-20.
3.2.1 Selection criteria for a suitable T cell receptor
The T cell clone whose TCR sequence was used for the generation of the transgenic mouse
had to fulﬁll certain criteria:
A) The TCR must be reactive and speciﬁc to PLP9-20 and PLP protein stimulation.
B) The TCR variable V and V regions must be stainable with available antibodies
for ﬂow cytometry in order to identify and trace the transgenic T cells later by ﬂow
cyotmetric analyses.
A) The TCR reacted highly to PLP9-20 peptide and PLP protein
The most fundamental criteria for the selection of the TCR was its reactivity and speciﬁcity
to PLP. Hybridoma T cells were cloned and screened for their reactivity to PLP9-20. When
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Figure 8: Stimulation of the T cell hybridoma clone D9-119-2 with PLP protein and PLP9-20
peptide. A) In vitro stimulation of the T cell hybridoma clone D9-119-2 with bone-marrow derived DCs
(BmDCs) pulsed with PLP9-20 peptide or non-cognate peptide (PLP172-183). The T cell hybridoma clone
responded highly to stimulation with its cognate antigen in a dose-dependent manner. It did not react
to stimulation with non-cognate peptide nor to BmDCs or media alone. B) In vitro stimulation of the T
cell hybridoma clone D9-119-2 with BmDCs pulsed with either PLP protein or OVA protein. The T cell
hybridoma clone responded to stimulation with PLP protein in correlation with the amount of protein that
was given, but not to stimulation with OVA protein. All BmDCs were able to stimulate the T cell hybridoma
clone when PLP9-20 peptide was added to the culture as a positive control. Proliferation was measured by
the production of IL-2 cytokine after 48 hours of stimulation.
we stimulated the T cell hybridoma clone D9-119-2 with titrated concentrations of PLP9-20
peptide, it showed a dose-dependent response with high reactivity to the peptide (Fig. 8 A).
Response to stimulation by a non-cognate peptide (PLP172-183) was not observed, showing
its speciﬁcity to PLP9-20. As we have generated the D9-119-2 clone by immunisation and
subsequent stimulation with synthetic PLP peptides, it needed to be veriﬁed that the TCR
was also reactive to PLP protein. To this end, bone-marrow derived dendritic cells (BmDCs)
were in vitro pulsed with PLP protein and co-cultured with the T cell hybridoma clone.
The reactivity of the hybridoma clone to PLP protein was evaluated by its IL-2 cytokine
production after 48 hours of stimulation. The D9-119-2 T cell hybridoma clone reacted
to stimulation with PLP protein but not when the BmDCs were pulsed with the control
protein OVA (Fig. 8 B). The strength of the stimulation response correlated to the amount
of PLP protein given to the BmDC culture.
Thus, the T cell hybridoma clone D9-119-2 was speciﬁc to PLP protein and reacted highly
to the peptide PLP9-20.
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Figure 9: Flow cytometry staining of the TCR of T cell hybridoma clone D9-119-2. Staining
of the T cell hybridoma clone D9-119-2 with antibodies for the use of TCR variable region V3.2 and V6.
The T cell hybridoma clone D9-119-2 was positive for TCR variable regions V3.2 and V6.
B) Antibodies were available to trace the TCR by ﬂow cytometry
Having ascertained that the T cell hybdridoma clone D9-119-2 was highly reactive to PLP,
the second criteria for a suitable TCR was that antibodies for both TCR variable V and
V regions were available in order to trace the fate of transgenic T cells in the TCR-PLP1
mouse by ﬂow cytometry at later time points. The TCR variable V6 chain was enriched
in PLP9-20-speciﬁc T cells, so we tested the T cell hybridoma clone D9-119-2 for the use of
the TCR variable region V6 together with available TCR variable V antibodies. Indeed,
the D9-119-2 hybridoma clone expressed the TCR variable region V6 together with the
TCR variable region V3.2 (Fig. 9). The ability for staining both TCR variable chains via
antibodies, facilitated the monitoring of the development of the PLP-speciﬁc T cells in the
TCR-transgenic mouse by ﬂow cytometry.
Taken together, the T cell hybridoma clone D9-119-2 was a good candidate for the genera-
tion of the PLP-speciﬁc TCR-transgenic mouse since it was highly responsive and speciﬁc
to the relevant PLP9-20 peptide (Fig. 8), and antibodies to stain the TCR were available
(Fig. 9). Furthermore, the D9-119-2 clone qualiﬁed as a good representative of PLP9-20-
speciﬁc T cells as it expressed TCR variable V6 region that was shown to be dominant in
PLP9-20-responding T cells (Fig. 7).
45
3 Results
3.2.2 Cloning of the TCR variable regions into cassette vectors
To introduce the TCR sequence of the hybridoma clone D9-119-2 into the genome and
to restrict its expression to T cells, we made use of the TCR expression vector cassettes
engineered by the lab of Benoist & Mathis [116]. The advantage of the pT- and pT-vector
cassettes is that they included essential promoter and enhancer elements for TCR expression
to ensure physiological expression levels of the receptor at the cell surface. Moreover, as
the vector cassettes already contained the constant C-region of the TCR, which is identical
for all T cells, only the rearranged TCR VJ- and TCR VDJ-segments needed to be
cloned into the vectors.
Cloning the TCR variable regions V3.2 and V6 into the pT- and
pT-vector cassettes
Before cloning, the RT-PCR products (generated with primers for the TCR V3.2 region
paired with a C primer and V6-C primers, respectively) were sequenced in order to
determine the exact usage of TCR VJ- and TCR VDJ-segments. The TCR segments
of the D9-119-2 T cell hybridoma clone were annotated in ensembl [www.ensembl.org] as the
following: the rearranged TCR VJ-segments were annotated as Trav9d-3.201 and Traj34-
201 and the TCR VDJ-segments as Trbv19-201, Trbd1, and Trbj1-1. The designation
V3.2 and V6 refer to the antibodies that speciﬁcally stained the rearranged V- and V-
regions, respectively, hence, one has to keep in mind that the exact genetic annotations are
the ones mentioned above. Here, we will refer to this TCR combination as TCR-PLP1. The
sequenced PCR fragments were then sub-cloned into the pT and pT-plasmids, generating
PLP-speciﬁc cassette vectors (pT-PLP1 and pT-PLP1), respectively.
Veriﬁcation of the expression and functionality of the TCR-PLP1 cassette
vectors
To test the vector plasmids for functionality, we stably transfected A5 T cell hybridomas
with both vector cassettes and tested the rearranged TCR-PLP1 for its proper expression
on the cell surface as well as its functionality and speciﬁcity to PLP9-20. We used A5 T cell
hybridomas for transfection, as these cells were in possession of all intracellular components
required for correct TCR signalling. The A5 T cell hybridoma clone recognises inﬂuenza
hemagglutinin peptide (HA107  119) in the context of I-Ed [150], and therefore, did not
respond intrinsically to peptides presented in the context of I-Ab on APCs of B6 origin.
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Figure 10: Conﬁrmation of proper surface expression and functionality of the pT-PLP1 and
pT-PLP1 cassette vectors. Stable transfection of A5 cells with both expression cassette vectors con-
taining V3.2 and V6 segments by electroporation. A) TCR-PLP1 transfected A5 cells showed expression
of the TCR-PLP1 TCR receptor (V3.2+ and V6+) on the cell surface. B and C) When TCR-PLP1
transfected A5 cells were stimulated with PLP9-20, they showed a response measured by the production of
GFP (B) and IL-2 (C). The transfected A5 cells did not respond to irrelevant peptide (OVA peptide in (B)
and PLP172-183 in (C)), conﬁrming the speciﬁcity to PLP9-20. Control hybridomas did not respond to any
stimulations.
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Furthermore, the A5 hybridoma cells were known to carry a TCR that was not composed
of V3.2 and V6, but is recognised by a speciﬁc antibody called 6.5. Therefore, we could
distinguish the introduced TCR-PLP1 from the TCR-HA on the cell surface. For transfec-
tion, the two linearised vector cassettes, pT-PLP1 and pT-PLP1, were electroporated
with A5 cells together with a linearised plasmid containing a NFAT-GFP reporter with a
puromycin resistance gene. Cells that were successfully transfected survived the selection
with puromycin and were subsequently screened for the expression of the introduced TCR
on the surface. In TCR-PLP1 transfected A5 T cell hybridoma cells, expression of the
PLP-speciﬁc TCR was detected by staining with antibodies for TCR V3.2 and TCR V6
(Fig. 10 A). The expressed PLP-speciﬁc TCR was then further tested for functionality and
speciﬁcity in a stimulation assay. To this end, we co-cultured transfected A5 hybridoma
cells together with APCs and cognate or non-cognate peptide. The stimulation was mea-
sured by the expression of the NFAT-GFP-reporter as well as by testing the supernatant for
the amount of IL-2 cytokine. TCR-PLP1 transfected hybridomas showed antigen-induced
NFAT activity in the presence of PLP9-20 peptide as detected by GFP expression (Fig.
10 B) and IL-2 production (Fig. 10 C). The strength of the response was dose-dependent,
while control hybridoma cells did not respond to PLP.
In summary, both TCR-PLP1 vector cassettes have been tested sucessfully for functionality
of the TCR and reactivity to PLP9-20.
3.2.3 Injection of pT-PLP1 and pT-PLP1 vector cassettes into mouse
oocytes
For the DNA injection into mouse oocytes, the prokaryotic parts of the vectors were removed
by enzymatic endonuclease digest and the linearised fragments were sent to the transgenic
core facility at the Max Planck Institute in Dresden. There, they were injected into fertilised
B6N oocytes, which were subsequently transplanted into foster mothers.
A total of nine TCR DNA-positive founder mice were obtained; two founder animals were
positive for both TCR V3.2 and TCR6 transgenes, while another two of the nine founders
expressed only the V chain, and the remaining ﬁve founders expressed only the V chain.
The ﬁve beta- and two alpha-single transgenic lines showed germ-line transmission of the
respective transgene, while both double-transgenic founders were not of further use: one did
not show TCR-PLP1-expression on lymphocytes and the other one did not give rise to any
progeny. Therefore, we crossed TCR-V3.2 single transgenic animals to TCR-V6 single
transgenic animals. Preliminary characterisation of diﬀerent combinations of the founder
animals showed identical phenotypes. For all conducted experiments, we made use of TCR
V3.2 founder No14 and TCR V6 founder No10, which will be referred to as TCR-PLP1
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transgenic mouse.
3.3 Negative selection and concomitant Treg induction of
TCR-PLP1+ T cells in the thymus
In the PLP-speciﬁc TCR-transgenic mice, we were now able to closely monitor the fate
of TCR-PLP1+ T cells after encountering PLP in the thymus. In order to evaluate the
modes and the extent of thymic tolerance induction, we compared TCR-PLP1PlpWT mice
to TCR-PLP1PlpKO animals. TCR-PLP1PlpKO mice are deﬁcient for PLP and, hence,
TCR-PLP1+ T cells will not be tolerised to PLP in the thymus. In contrast to TCR-
PLP1PlpWT mice, where PLP is presented in the thymus as tissue-restricted self-antigen
and central tolerance will be induced.
The presence (TCR-PLP1PlpWT) or absence (TCR-PLP1PlpKO) of the self-antigen PLP
in the thymus had no impact on total thymic cellularity (Fig. 11 A). Detailed charac-
terisation of the T cell compartments revealed a signiﬁcant loss of CD4SP T cells in the
TCR-PLP1PlpWT mice as compared to TCR-PLP1PlpKO mice (20.6  3.6 x 106 CD4SP
cells in TCR-PLP1PlpKO thymi vs. 4.9  0.8 x 106 CD4SP cells in TCR-PLP1PlpWT
thymi) (Fig. 11 B). All other compartments in the thymus showed the same cellularity in
TCR-PLP1PlpWT and TCR-PLP1PlpKO mice.
The reduction in the CD4SP compartment of TCR-PLP1PlpWT mice suggested strong neg-
ative selection of TCR-PLP1+ T cells in the thymus. In 3-week-old TCR-PLP1PlpKO mice
(no cognate antigen expressed), the percentage of thymic CD4+ T cells was 16.9%  1.9%
(Fig. 11 C, ﬁrst column) with the majority of these being TCR-PLP1-speciﬁc T cells
(85.5%  3.2%) (Fig. 11 C, second column). In TCR-PLP1PlpWT mice, in contrast, where
PLP was presented as endogenous antigen in the thymus, we saw a reduction in the percent-
age of CD4SP thymocytes (4.02%  0.4%) (Fig. 11 C) as well as in absolute cell numbers
(see Fig. 11 B). Furthermore, within the CD4SP compartment, we observed a reduction of
TCR-PLP1-speciﬁc T cells (51.1%  4.1% in TCR-PLP1PlpWT mice vs. 85.5%  3.2% in
TCR-PLP1PlpKO mice).
It was shown that self-antigen encounter in the thymus can also drive auto-reactive T cells
into the regulatory T cell lineage [151, 152]. Therefore, we analysed the abundance of
TCR-PLP1-speciﬁc Treg cells. While in TCR-PLP1PlpKO mice only a minuscule fraction of
TCR-PLP1+ T cells was deviated into Foxp3+ Treg cells (0.4%  0.1%), the percentage of
TCR-PLP1+ T cells selected as regulatory T cells in TCR-PLP1PlpWT mice was 10-times
higher (4%  0.6%) (Fig. 11 C third column). In absolute cell numbers, 10.6  1.8 x 104
TCR-PLP1+ Foxp3+ Treg cells were present in TCR-PLP1PlpWT mice as compared to only
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Figure 11: Flow cytometry analysis of the thymi of young TCR-PLP1PlpWT and TCR-
PLP1PlpKO mice. A and B) Absolute cell numbers of the total thymus (A) or within diﬀerent com-
partments of the thymus (B). Shown is the average mean in absolute numbers of thymocytes x 106 at the
age of 3 weeks with the standard error of the mean (SEM). A) TCR-PLP1PlpKO and TCR-PLP1PlpWT
mice demonstrate no diﬀerence in total thymic cellularity. B) Absolute cell number of thymocytes in the re-
spective compartment of T cell development: DN, DP, CD8SP and CD4SP cells. In all compartments other
than CD4SP, the cell number did not signiﬁcantly diﬀer between TCR-PLP1PlpKO and TCR-PLP1PlpWT
mice. In the CD4SP compartment, TCR-PLP1PlpWT mice showed a signiﬁcant reduction. C and D) Flow
cytometry analysis of the thymic phenotype of TCR-PLP1PlpWT mice in comparison to TCR-PLP1PlpKO
mice at the age of 3 weeks in percentage (C) and in absolute cell numbers x 106 (D). Shown is the percent-
age or absolute cell number of CD4SP cells in the thymus (ﬁrst column), the percentage of TCR-PLP1+
cells within the CD4SP compartment (second column), the percentage of Foxp3+ regulatory T cell in the
TCR-PLP1+ cell population (third column) and the percentage of mature cells within the TCR-PLP1+
cell population in the thymus (fourth column). Depicted are littermates representative for the observed
phenotype. The numbers above the gates represent the mean average of all animals of the same cohort 
the standard error of the mean (SEM). Tolerance induction to PLP in the thymus of TCR-PLP1PlpWT mice
was conducted by negative selection and deviation of TCR-PLP1+ T cells into the regulatory T cell lineage
at the CD4SP stage. TCR-PLP1PlpKO: n=8, TCR-PLP1PlpWT: n=10.
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5.9  1.3 x 104 in TCR-PLP1PlpKO mice (Fig. 11 D).
Taken together, when antigen was present in the thymus, we observed a strong deletion of
mature TCR-PLP1+ T cells together with concomitant Treg induction.
As we observed a late deletion of TCR-PLP1-transgenic T cells at the CD4SP stage, we also
analysed the population of TCR-PLP1+ T cells in the CD4SP compartment with respect
to their maturation status. T cells with a mature phenotype (designated as CD24loCD69lo)
have already passed negative selection and Treg induction and were ready to leave the thy-
mus as naive T cells. In TCR-PLP1PlpKO mice, half of the TCR-PLP1+ CD4SP cells were
mature (49.55%  3.1%) (Fig. 11 C, fourth column). In TCR-PLP1PlpWT mice, on the
other hand, the mature population of TCR-PLP1+ T cells was considerably diminished
(26.9%  4.1%).
As we have observed reduced maturation of TCR-PLP1+ CD4SP cells in the thymus of
TCR-PLP1PlpWT animals, the frequency of CD4+ TCR-PLP1+ T cells arriving in the
spleen was correspondingly low (9.1% 0.7% in TCR-PLP1PlpWT compared to 74.2% 4.1%
in TCR-PLP1PlpKO mice) (Fig. 12 second column). In line with the overall thymic reduc-
tion of CD4+ cells, only 1.2%  0.2% CD4+ T cells were found in the spleen of these mice.
Notably, a large proportion of these TCR-PLP1+ T cells were Treg cells (38.4%  1.7%)
in contrast to the low percentage of TCR-PLP1+ Treg cells in TCR-PLP1PlpKO mice
(1.2%  0.3%) (Fig. 12 third column).
Taken together, by comparing T cell development of TCR-PLP1 transgenic mice in the
presence and absence of the cognate self-antigen PLP, we observed central tolerance induc-
tion to PLP in the thymus with an even more pronounced reduction of TCR-PLP1+ T cells
and concomitant induction of Tregs in the periphery.
3.4 Individual contribution of thymic antigen presenting cell
subsets to tolerance induction to PLP
As we observed that central tolerance to PLP was induced via both mechanisms (clonal
deletion of TCR-PLP1+ T cells and Treg induction), we next investigated the contributions
of the individual thymic antigen presenting cell types to central tolerance to PLP.
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Figure 12: Flow cytometry analysis of peripheral phenotype in young PLP-TCR1 transgenic
animals. Flow cytometry analysis of the peripheral phenotype in TCR-PLP1PlpWT mice in comparison to
TCR-PLP1PlpKO mice at the age of 3 weeks. Shown is the percentage of CD4+ cells in the spleen (ﬁrst
column), the percentage of TCR-PLP1+ cells within the CD4+ compartment (middle column), and the
percentage of Foxp3+ regulatory T cells in the TCR-PLP1+ cell population (third column). The phenotype
of tolerance induced in the thymus of TCR-PLP1PlpWT mice translated into the periphery with deletion
and deviation of TCR-PLP1+ T cells into the Treg lineage. Depicted are littermates representative of the
observed peripheral phenotype. The numbers above the gates represent the mean average of all animals
of the same cohort  the standard error of the mean (SEM). TCR-PLP1PlpKO: n=8; TCR-PLP1PlpWT:
n=10.
3.4.1 Expression of PLP in the thymus
PLP is expressed in TECs and to a lesser extent in thymic DCs
To delineate which APC subset contributed to tolerance induction to PLP, the expression
patterns of PLP within diﬀerent antigen presenting cell types of the thymus were analysed.
The amount of PLP mRNA in FACS-sorted thymic cell populations was quantiﬁed by
qRT-PCR. Care was taken that the ampliﬁcation spanned the core epitope PLP11-18. We
distinguished between the thymic APC subtypes DCs, cTECs, and mTECs, with the mTEC
population further subdivided into a mTEChi and a mTEClo population with respect to
their MHCII-expression level. CD4SP thymocytes were included as a negative control.
Equally high expression of PLP mRNA in both mTEChi and mTEClo populations was
detected, while thymic DCs expressed PLP to a 4-times lower extent (Fig 13). CD4SP T
cells did not show expression of PLP, as expected. cTECs expressed PLP at the highest
level, twice as much as the expression level of PLP in mTECs. The expression pattern of
PLP mRNA was in line with previous reports using semi-quantitative PCR [1,3], and more
recently by a RNA sequencing approach of the entire transcriptome [65].
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Figure 13: Expression of PLP mRNA in thymic APC subsets. Relative mRNA expression levels of
PLP in distinct FACS-sorted thymic subsets normalised to thymic DCs (tDCs). cTECs as well as mTECs
expressed high amounts of PLP mRNA, while DCs showed a 4-times lower expression level. CD4SP T cells
did not express PLP mRNA. Analysed animals were 10 days of age. The mean average of PLP expression
is shown in arbitrary units (AU)  the standard error of the mean (SEM).
PLP expression by non-hematopoietic cells in the thymus is suﬃcient for
deletion and concomitant Treg induction
Since we have shown that both the non-hematopoietic and the hematopoietic compartment
in the thymus expressed PLP at mRNA level, we next investigated which of these compart-
ments mediated tolerance induction to PLP.
For this purpose, we performed thymus transplantation experiments with selective PLP ex-
pression in cells of the hematopoietic compartment only, in cells of the non-hematopoietic
compartment only, in neither cell type or in both. To do so, we grafted deoxyguanosine-
treated thymi from E14 WT or E14 PLP-/- fetuses under the kidney capsule of TCR-
PLP1PlpWT or TCR-PLP1PlpKO mice. By 2-deoxyguanosine (dGuo) treatment, all hemato-
poietic cells of the fetal thymus have been eliminated prior to transplantation [153]. The
transplanted thymi were then seeded, analogues to a normal thymus, with hematopoietic
cells of host origin only.
When PLP was expressed only in the dGuo-resistant compartment, i.e. TECs, but not in
cells of the hematopoietic system (WT thymi transplanted into TCR-PLP1PlpKO mice), it
faithfully recapitulated the phenotype of deletion and regulatory T cell induction of TCR-
PLP1+ cells as seen in TCR-PLP1PlpWT mice when compared to TCR-PLP1PlpKO mice
(Fig. 14 A, B, and C). In contrast, when PLP was expressed only in hematopoietic cells
of the host (PLP-/- thymi transplanted into TCR-PLPplpWT mice), the phenotype did
not show clonal deletion nor Treg induction of TCR-PLP1+ T cells but resembled a non-
tolerised T cell population like in TCR-PLP1PlpKO mice. Thus, we observed tolerance in
transplanted thymi when PLP was expressed in the thymic epithelial compartment, but not
when it was only expressed by cells of the hematopoietic compartment. Since we have seen
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that TCR-PLP1 transgenic T cells were deleted late, in T cell development at the CD4SP
stage, the eﬀect of PLP expression only in TECs or only in cells of bone-marrow origin
was additionally assessed by examining the abundance of mature cells in the transplanted
thymi. In transplants with TECs of WT origin, the frequency of TCR-PLP1+ mature cells
in all thymocytes was highly diminished compared to transplanted thymi that were PLP-
deﬁcient (Fig. 14 D). This data clearly shows that PLP expression by TECs was suﬃcient
to mediate central tolerance to PLP. Furthermore, the abundance of mature TCR-PLP1+
T cells in transplants with PLP expression only in the hematopoietic compartment (PLP-/-
thymi transplanted into TCR-PLPplpWT mice) was not diﬀerent when compared to mice
with PLP deﬁciency in both compartments.
In summary, these results showed that expression of PLP by bone-marrow derived cells did
not mediate tolerance induction to PLP, whereas expression of PLP by TECs was suﬃcient
to induce clonal deletion as well as regulatory T cell induction of PLP-speciﬁc T cells.
PLP expression in TECs is crucial for central tolerance induction to PLP
To conﬁrm the ﬁnding that PLP expression in thymic epithelium cells was suﬃcient and
necessary to induce tolerance, we abrogated PLP expression speciﬁcally in TECs by crossing
the Foxn1-driven Cre-recombinase together with a loxP-site ﬂanked Plp allele to the TCR-
PLP1 transgenic mice. This yielded a conditional knock-out of Plp in all Foxn1-expressing
cells, i.e. cTECs and mTECs.
Our data showed that deletion of PLP expression speciﬁcally in TECs, abrogated central
tolerance to PLP completely. The TCR-PLP1Plpﬂ/ﬂ Foxn1-Cre mouse, recapitulated pre-
cisely the phenotype seen in animals with a deﬁciency for PLP in all cells. No reduction of
CD4+ TCR-PLP1+ T cells or of the overall CD4SP compartment was seen (Fig. 15 A and
B). Furthermore, no Tregs were induced in the thymi of TCR-PLP1Plpﬂ/ﬂ Foxn1-Cre mouse
(Fig. 15 C). This proved an exclusive and crucial role of TECs contributing to central
tolerance induction by expression of the antigen PLP.
In sum, PLP expression in TECs was necessary and suﬃcient for tolerance induction to
PLP in the thymus.
3.4.2 Presentation of PLP in the thymus
Having established that expression of PLP in TECs was suﬃcient and necessary for the dif-
ferentiation of TCR-PLP1+ T cells into Treg cells as well as the deletion of TCR-PLP1+ thy-
mocytes, it remained open which antigen presenting cells in the thymus actually presented
54
3.4 Individual contribution of thymic antigen presenting cell subsets to tolerance induction to PLP
0
10
20
30
40
50
50
60
70
80
90
100
0.0
0.5
1.0
1.5
2.0
2.5
p = 0.01
p = 0.003
p = 0.03 p = 0.003
C
D
4
S
P
 c
e
lls
 
o
f 
tr
a
n
sp
la
n
te
d
 t
h
y
m
u
s 
[%
]
TC
R
-P
LP
1
+
  c
el
ls
o
f C
D
4
S
P
 c
e
lls
 o
f 
tr
a
n
sp
la
n
t
 [%
]
transplant: WT PLP-/-
WT
WT
WTPLP-/-
PLP-/-
PLP-/-host: 
transplant: WT PLP-/-
WT
WT
WTPLP-/-
PLP-/-
PLP-/-host: 
transplant: WT PLP-/-
WT
WT
WTPLP-/-
PLP-/-
PLP-/-host: 
CD4SP cells TCR-PLP1+  cells
Foxp3+ T
reg
 cells
A B
C
0
5
10
15
20
25
m
a
tu
re
 T
C
R
-P
LP
1
+
 C
D
4S
P
 c
e
lls
 
o
f 
tr
an
sp
la
n
te
d
 t
h
y
m
u
s 
[%
]
mature TCR-PLP1+ cellsD
transplant: WT PLP-/-
WT
WT
WTPLP-/-
PLP-/-
PLP-/-host: 
ns
p = 0.0007
p = 0.001
p < 0.0001
ns p = 0.0003
ns
p < 0.0001
p = 0.025
p = 0.0006
ns p = 0.005
ns
p = 0.0004
 ns
p = 0.0005
ns p = 0.01
p = 0.03
p < 0.0001
F
o
x
p
3
+
 C
D
2
5
+
 c
e
ll
s 
o
f 
T
C
R
-P
L
P
1
+
 C
D
4
S
P
 c
e
ll
s 
o
f 
tr
a
n
sp
la
n
t 
[%
]
Figure 14: Transplantation experiments to investigate the contribution of PLP expression in
the hematopoietic and non-hematopoietic compartments for tolerance induction. Transplanta-
tion of WT or PLP-/- thymi (transplants) under the kidney capsule of either TCR-PLP1PlpWT or TCR-
PLP1PlpKO mice (hosts). The graph shows (A) the percentage of CD4SP cells within the transplanted thymi,
(B) the percentage of TCR-PLP1+ cells within the CD4SP compartment of the transplanted thymi, (C) the
percentage of Foxp3+ Treg cells in the CD4+ TCR-PLP1+ T cell population of the transplants, and (D) the
percentage of mature TCR-PLP1+ T cells of all thymocytes in the transplants. PLP expression by cells of
non-hematopoietic origin induced tolerance to PLP as seen in TCR-PLP1PlpWT mice. Data were combined
from two separate but identical experiments. WT transplants into TCR-PLP1PlpWT hosts: n=11; WT
transplants into TCR-PLP1PlpKO hosts: n=10; PLP-/- transplants into TCR-PLP1PlpWT hosts: n=15;
PLP-/- transplants into TCR-PLP1PlpKO hosts: n=11.
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Figure 15: Abrogation of PLP expression exclusively in TECs. The bar diagram shows (A) the
percentage of CD4SP cells within the thymus, (B) the percentage of TCR-PLP1+ cells within the thymic
CD4SP compartment, and (C) the percentage of Foxp3+ Treg cells in the CD4SP TCR-PLP1+ population.
Deletion of PLP expression only in TECs showed a complete abrogation of thymic tolerance induction in
TCR-PLP1PlpWT mice. Depicted is the mean average of each group with the standard error of the mean
(SEM). TCR-PLP1PlpKO: n=8; TCR-PLP1Plpﬂ/ﬂ: n=2; TCR-PLP1Plpﬂ/ﬂ Foxn1-Cre: n=2.
PLP for tolerance induction. To test this, we selectively manipulated PLP presentation in
diﬀerent APC subsets.
CD11c+ dendritic cells do not present PLP for tolerance induction
It was shown that antigen can be transferred unidirectional from mTECs to thymic den-
dritic cells, so that DCs can present antigens that they do not express themselves [82, 83].
Even though we have established that the expression of PLP in bone marrow-derived cells
was not relevant for tolerance induction, it could still be that thymic DCs receive TRA
peptide or even pre-formed TRA-loaded pMHC complexes from TECs [84]. To investigate
to what extent thymic DCs (as major antigen presenting cell type of the hematopoietic
system) contributed to the presentation of PLP and to tolerance induction in the thy-
mus, we crossed TCR-PLP1 transgenic mice to DC mice. In DC mice, toxic diphteria
toxin expression is driven by the Cre-recombinase that is under the control of the CD11c
promoter [154]. Consequently in these mice, conventional CD11c+ DCs are constitutively
deleted. In the thymus of TCR-PLP1PlpWT DC mice, CD11c+ DCs were absent and
could therefore not contribute to the presentation of PLP. Thus, we assessed the necessity
of PLP presentation by DCs for tolerance induction by comparing the thymic phenotype of
TCR-PLP1PlpWT DC mice to littermates that did not lack DCs (TCR-PLP1PlpWT).
We found that in TCR-PLP1PlpWT DC mice, the percentage of CD4SP cells (6.6 
1.1), the percentage of CD4SP TCR-PLP1+ T cells (60.8  8.9), and the percentage of
PLP1-speciﬁc Tregs (2.96  0.3) were not signiﬁcantly diﬀerent from DC-suﬃcient TCR-
PLP1PlpWT control littermates (4.5  0.8 CD4SP cells, 60.0  4.3 CD4SP TCR-PLP1+
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Figure 16: Central tolerance induction to PLP in the absence of DCs. Thymic analysis of TCR-
PLP1PlpWT DC mice compared to TCR-PLP1PlpWT mice. DCs mice are CD11c-Cre/R-DTA mice
that lack all CD11c+ dendritic cells due to the toxic expression of diphteria toxin alpha (DTA) that was
introduced to the Rosa26-locus. The bar diagrams show (A) the percentages of CD4SP cells within the
thymus, (B) the percentage of TCR-PLP1+ cells within the thymic CD4SP compartment, and (C) the
percentage of Foxp3+ Treg cells in CD4SP TCR-PLP1+ cell population. CD11c+ DCs did not contribute to
the induction of tolerance in the thymus of TCR-PLP1 mice. Depicted is the mean average of each group
with the standard error of the mean (SEM). TCR-PLP1PlpKO: n=8; TCR-PLP1PlpWT CD11c-Cre+ or
DTA+: n=4; TCR-PLP1PlpWT DC: n=6.
T cells, and 3.2  0.6 TCR-PLP1+ Foxp3+ Treg, respectively) (Fig. 16). Thus, we observed
a tolerised CD4+ T cell pool in thymi with PLP suﬃcient TECs irrespective of the presence
or absence of CD11c+ DCs. Presented data clearly indicate that central tolerance induction
is mediated by the non-hematopoietic compartment and does not depend on DCs.
We conclude that thymic DCs were dispensable for central tolerance induction to PLP and
antigen-transfer from mTECs to DCs for presentation of PLP was not important.
Taken together, thymic DCs did not contribute to the expression nor to the presentation
of PLP needed to tolerise PLP-speciﬁc autoreactive T cells.
Direct expression and presentation of PLP by mTECs
Since thymic DCs were not involved in central tolerance induction to PLP, we further inves-
tigated the roles of cTECs and mTECs to central tolerance induction to PLP. To this end,
we wanted to eliminate the capacity for PLP presentation of one or the other cell subset. A
complete KO of MHCII expression on mTEC cells was not feasible for two reasons: First, no
mTEC nor cTEC lineage-speciﬁc Cre-line has been reported, so that the expression of PLP
could not be deleted by the loxP-Cre-system in an exclusive manner. Second, as the mat-
uration and homeostasis of mTEC cells is dependent on interactions between mTECs and
auto-reactive T cells via the MHCII receptor, a complete MHCII-/- in mTECs would impair
the proper development of mTECs and lead to a perturbed medullary architecture [155].
Therefore, we crossed the TCR-PLP1 transgenic mice to major histocompatibility complex
class II transactivator (CIITA) knockdown mice (C2TAkd). In C2TAkd mice, the MHCII
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expression level on mTEChi is reduced to 10% of WT levels [77]. This is due to an AIRE-
promoter-driven shRNA which knocks down C2TA expression, which subsequently leads to
a diminished expression of MHCII on the cell surface.
We wanted to examine if direct presentation of PLP by mTECs was suﬃcient for establish-
ing deletion and concomitant Treg induction of TCR-PLP1+ T cells. We hypothesised that
elimination of MHC class II expression on medullary TECs would demonstrate the loss of
PLP presentation by mTECs and, consequently, show the direct contribution of mTECs to
tolerance induction to PLP.
When the presentation capacity of mTECs was diminished by C2TAkd, we observed less
clonal deletion of CD4SP and CD4SP TCR-PLP1+ T cells compared to TCR-PLP1PlpWT
mice: TCR-PLP1PlpWT C2TAkd showed 9.8% 0.8% CD4SP cells compared to 4.02% 0.4%
in TCR-PLP1PlpWT mice and 72.2%  1.9% CD4SP TCR-PLP1+ T cells compared to
51.1%  4.1% in TCR-PLP1PlpWT mice (Fig. 17 A and B). In addition, we detected a
drastic reduction in the percentage of thymic PLP1-speciﬁc Tregs in C2TAkd mice (1.5%
 0.3%) compared to TCR-PLP1PlpWT mice (4.1%  0.6%) (Fig. 17 C). Thus, reducing
the presentation capacity in mTEChi aﬀected central tolerance induction to TCR-PLP1+
T cells. Interestingly, the C2TAkd genotype did not lead to a complete loss of tolerance to
PLP.
In summary, by reducing the presentation capacity of mTEChi, we could show that mTEChi
contribute to central tolerance. However, this approach does not exclude a potential con-
tribution of cTECs and mTEClo to tolerance induction.
Taken together, we conclude that not only the expression of PLP by mTECs but also the
direct presentation of the antigen by this cell type was indispensable for tolerance induction
to PLP.
3.5 The role of AIRE in central tolerance induction to PLP
Through changes in the transcriptional landscape of a large variety of genes, AIRE allows
AIRE+ mTECs to express an incredible amount of otherwise tissue-restricted antigens
[2,5,90]. We wanted to see whether tolerance induction to PLP, although being an atypical
tissue-restricted antigen due to its expression also in cTECs, DCs and mTEClo, would also
be regulated by AIRE.
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Figure 17: Reduction of the presentation capacity on mTECs by C2TAkd. The bar diagrams show
(A) the percentages of CD4SP cells within the thymus, (B) the percentage of TCR-PLP1+ cells within the
thymic CD4SP compartment, and (C) the percentage of Foxp3+ Treg cells in the CD4SP TCR-PLP1+ cell
population. Reduction of the presentation capacities on mTECs by C2TAkd led to a diminished tolerance to
PLP in TCR-PLP1PlpWT C2TAkd animals. mTECs mediate clonal deletion and Treg cell induction by direct
presentation. Depicted is the mean average of each group with the standard error of the mean (SEM). TCR-
PLP1PlpKO: n=8; TCR-PLP1PlpWT: n=10; TCR-PLP1PlpKO C2TAkd: n=3; TCR-PLP1PlpWT C2TAkd:
n=5.
3.5.1 AIRE inﬂuences PLP expression
To see if AIRE controlled the expression of PLP, we performed qRT-PCR analysis for PLP
expression in the thymic mTEChi population of WT and Aire-/- animals. We detected a
6-fold reduction of the PLP mRNA expression in AireKO mTEChi cells compared to the
mTEChi population of WT mice (Fig. 18). Thus, AIRE regulated the expression of PLP
in mTEChi cells. In future studies, we will address if AIRE also inﬂuences the expression
of PLP in the other stromal subsets cTEC and mTEClo, and will also distinguish between
mTEChi AIRE-positive and mTEChi AIRE-negative cell subsets.
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Figure 18: AIRE regulates the expression of PLP in mTEChi. The relative mRNA expression of
PLP in AireKO mTEChi compared to the expression level of WT mTEChi. The expression level of PLP was
normalised to WT mTEChi. A deﬁciency of AIRE reduced the expression of PLP mRNA in the mTEChi of
the thymus. The bar diagram shows the expression levels of one preliminary experiment in arbitrary units
(AU).
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Figure 19: Loss of central tolerance induction when AIRE is absent. The bar diagrams show
(A) the percentages of CD4SP cells within the thymus, (B) the percentage of TCR-PLP1+ cells within the
thymic CD4SP compartment, and (C) the percentage of Foxp3+ Treg cells within the CD4SP TCR-PLP1+
T cell population. Deﬁciency of AIRE abolished central tolerance induction to PLP. Depicted is the mean
average of each group with the standard error of the mean (SEM) as error bars.
TCR-PLP1PlpKO: n=8; TCR-PLP1PlpWT: n=11; TCR-PLP1PlpKO AireKO: n=3; TCR-PLP1PlpWT
AireKO: n=6.
3.5.2 AIRE deﬁciency abrogates central tolerance induction to PLP
Given that AIRE deﬁciency reduced PLP expression in the mTEChi population, we further
speculated on a role for AIRE in central tolerance induction to PLP.
To address this, we crossed TCR-PLP1 transgenic mice to the Aire-/- mice and analysed
their thymic phenotype compared to AIRE-suﬃcient littermates. AIRE deﬁciency com-
pletely abolished the deletion and regulatory T cell induction of TCR-PLP1+ T cells that
we had observed before in TCR-PLP1PlpWT mice. TCR-PLP1PlpWT AireKO mice had a
signiﬁcantly higher frequency of CD4SP cells than TCR-PLP1PlpWT mice (12.2%  1.4%
in TCR-PLP1PlpWT AireKO mice compared to 4.02%  0.4% in the AIRE-suﬃcient TCR-
PLP1PlpWT mice) (Fig. 19 A). Also within the CD4SP compartment, TCR-PLP1+ T cells
were no longer deleted (CD4SP TCR-PLP1+ cells: 92.2%  1.6% in TCR-PLP1PlpWT
AireKO mice compared to 51.1%  4.1% in the AIRE-suﬃcient TCR-PLP1PlpWT mice)
(Fig. 19 B). Moreover, no selection of TCR-PLP1+ regulatory T cells was observed when
AIRE was deﬁcient (0.1% 0.02% in TCR-PLP1PlpWT AireKO mice compared to 4.1% 0.6%
in the AIRE-suﬃcient TCR-PLP1PlpWT mice) (Fig. 19 C). This data clearly showed that
AIRE expression is crucial for Treg induction.
In summary, tolerance induction to PLP was greatly impaired in the absence of AIRE,
which indicates mTEChi (as the exclusive AIRE expressing subset) are the main players in
central tolerance to PLP.
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3.6 Central tolerance in TCR-PLP1 mice is age-dependent
Central tolerance induction was lost with age
So far, we have analysed central tolerance induction in the TCR-PLP1 mouse model at the
age of 3 weeks. In these mice, we observed TCR-PLP1-speciﬁc T cells to be deleted as
well as deviated into the regulatory T cell lineage. Crucial for tolerance induction was the
expression and presentation of PLP by mTECs (see section 3.4).
Next, we wanted to assess the state of tolerance induction in adult mice, as we observed no
signs of auto-immunity in aged mice. Analysing animals at the age of 8 weeks, we observed
a complete loss of central tolerance induction to PLP also in mice that were suﬃcient for
PLP (Fig. 20). In 8-week-old TCR-PLP1PlpWT mice, the CD4SP compartment was not
reduced (34.7%  2.5%) compared to TCR-PLP1PlpKO mice (36.8%  1.6%) (Fig. 20, ﬁrst
column). Also, the TCR-PLP1+ T cells were no longer deleted in TCR-PLP1PlpWT mice
(92.7%  1.6%), nor were TCR-PLP1-speciﬁc Treg cells induced (0.4%  0.2%) (Fig. 20,
second and third column). Consistently, in the 8-week-old thymi of TCR-PLP1PlpWT mice,
mature T cells increased to 55.1%  3.2% of TCR-PLP1+ T cells, which represented similar
levels of mature cells as in TCR-PLP1PlpKO mice (63.2%  1.4%) (Fig. 20, fourth column).
Thus, adult TCR-PLP1PlpWT mice appear to have lost central tolerance induction in the
thymus completely.
Time-window for negative selection and Treg induction
Due to this unexpected observation, we addressed central tolerance induction in relation
to age in more detail. To see if there is a certain time-window for central tolerance, we
analysed the thymic phenotype at time-points ranging from the ﬁrst day after birth up to
12 weeks of age. In the ﬁrst 2 weeks of life, we assessed the phenotype of central tolerance
induction every second day, while after 4 weeks it was evaluated only every other week. We
observed central tolerance to PLP to be age-dependent (Fig. 21): In the ﬁrst 3 days after
birth, the thymi of both TCR-PLP1PlpWT and TCR-PLP1PlpKO mice showed comparable
percentage of CD4SP and TCR-PLP1+ T cells. After that, TCR-PLP1+ T cells in TCR-
PLP1PlpWT mice were subject to central tolerance induction: in the thymi of these mice
we observed strong deletion of CD4SP and TCR-PLP1+ T cells that peaked at 2  3 weeks
of age (Fig. 21 A and B). Then, central tolerance induction gradually diminished until it
was completely lost at the age of 6 weeks.
Inversely correlated to the deletion of TCR-PLP1+ T cells, we observed the induction of
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Figure 20: Thymic phenotype of adult TCR-PLP1PlpKO and TCR-PLP1PlpWT mice. Represen-
tative littermates of TCR-PLP1PlpKO and TCR-PLP1PlpWT mice were analysed for their thymic phenotype
at the age of 8 weeks. Shown is the percentage of CD4SP cells in the thymus (ﬁrst column), the percentage of
TCR-PLP1+ cells within the CD4SP compartment (second column), the percentage of Foxp3+ regulatory
T cell in the CD4SP TCR-PLP1+ T cell population (third column), and the percentage of mature cells
within the TCR-PLP1+ T cell population in the thymus (fourth column). Adult TCR-PLP1PlpWT mice
have completely lost tolerance to PLP in the thymus. The numbers above the gates represent the mean
average of all animals of the same cohort with the standard error of the mean (SEM). TCR-PLP1PlpKO:
n=4; TCR-PLP1PlpWT: n=7.
TCR-PLP1+ Treg cells (Fig. 21 C): In the ﬁrst few days, emergence of TCR-PLP1+ Foxp3+
Treg cells was neglegible. At 1 week, PLP-speciﬁc Tregs started to appear and at the age of
3 weeks they composed around 4% of the CD4SP TCR-PLP1+ T cell population. These
observations are consistent with a recent study, which also reported thymic Treg cells to
appear in a polyclonal CD4SP compartment from day 4 on [156].
In conclusion, we observed a time-window for central tolerance induction to PLP in TCR-
PLP1PlpWT mice. Negative selection of TCR-PLP1+ T cells was operating in the thymus
from day 3 until 6 weeks of age, whereas PLP-speciﬁc Tregs started to accumulate only after
the ﬁrst week in TCR-PLP1PlpWT mice and induction lasted until 6 weeks of age. In adult
mice older than 6 weeks, central tolerance was completely lost.
No diﬀerential expression of PLP in the aged thymus
We hypothesised that the loss of tolerance in TCR-PLP1PlpWT mice with age was a con-
sequence of a potential loss or decrease in PLP expression in the thymus. Therefore, we
compared the expression level of PLP mRNA in thymi of young (10 days of age) and adult
WT animals (10 weeks of age). Due to technical limitations to isolate cTECs from adult
thymi, we analysed only mTEClo, mTEChi, and thymic DCs.
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Figure 21: Central tolerance induction to PLP is conﬁned to a time-window. The thymic
phenotype of TCR-PLP1PlpKO and TCR-PLP1PlpWT mice was assessesd at diﬀerent time points. A gradual
loss of thymic tolerance was observed in TCR-PLP1PlpWT mice. Shown is (A) the percentages of CD4SP
cells in the thymus plotted against the age of the mice, (B) the percentages of TCR-PLP1+ cells within the
CD4SP compartment as a function of the animal’s age, and (C) the percentages of Foxp3+ regulatory T
cells in the CD4SP TCR-PLP1+ T cell population plotted against the age of the mice. Time points analysed
ranged from 1 day after birth to 12 weeks after birth.
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Figure 22: Expression of PLP mRNA in thymic APC subsets at diﬀerent ages. Relative mRNA
expression of PLP in the thymic APC subsets mTEClo, mTEChi, and thymic DCs (tDCs), normalised to
the expression levels of DCs in 10-day-old animals. Young mice were 10 days of age, old mice were 10 weeks
of age. PLP was not diﬀerentially expressed in young versus old thymic APC subsets. The bar diagram
shows the mean average of 3 individual experiments in arbitrary units (AU). Error bars are depicted as the
standard error of the mean (SEM).
We did not detect a signiﬁcant diﬀerence in PLP mRNA expression in old versus young
thymic APC subsets (Fig. 22). Hence, the change in central tolerance between young and
adult TCR-PLP1PlpWT mice cannot be based on a diﬀerential expression of the antigen
in the thymus. Further possibilities, like a diﬀerential translation of PLP protein, will be
addressed in future studies.
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Negative selection operates in the thymic medulla via two mechanisms in order to maintain
immunological self-tolerance: clonal deletion of potentially hazardous self-reactive T cells,
and the production of CD4+ CD25+ Foxp3+ regulatory T cells (Treg cells), which act in
the periphery to control self-reactive T cells that escape thymic selection. The contribution
of the diﬀerent cellular subsets and the exact modalities for the choice of either negative
selection or Treg induction are not yet fully deciphered.
Much progress in understanding the mechanisms of central tolerance has been made by
studying fate decisions in TCR-transgenic animals. In many studies, TCR-transgenic mice
have been used which express a TCR-speciﬁcity against a transgenic gene such as chicken
ovalbumin (OVA), inﬂuenza hemagglutinin (HA) or human C-reactive protein (hCRP) [74,
85,157]. The expression of these introduced neo-self-antigens mostly exceeded physiological
expression levels of thymic self-antigens and added yet another concern to the already
artiﬁcial system.
We have generated a model system for the study of central tolerance induction towards an
endogenous tissue-restricted antigen. In the novel TCR-PLP1 transgenic mouse, T cells
are reactive to an immuno-dominant epitope of myelin proteolipid protein (PLP) in the
context of I-Ab. This mouse model allowed us to study the fate of thymocytes which see
their cognate antigen PLP9-20 at physiologic levels. Furthermore, as the B6 background has
strong tolerance mechanisms against PLP [3,142], we were able to investigate what type of
APC and further factors contributed to tolerance induction to PLP.
Presented data of the model system TCR-PLP1 indicate the following implications for
tolerance induction to the self-antigen PLP:
1. Central tolerance to PLP is induced by clonal deletion and concomitant Treg induction
of TCR-PLP1+ T cells.
2. Thymic medullary epithelial cells (mTECs) express and present the antigen PLP au-
tonomously. Tolerance to PLP is mediated by mTECs exclusively, while thymic DCs
do not contribute to tolerance induction.
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3. The expression of PLP mRNA in mTEChi is controlled by AIRE. AIRE deﬁciency
abrogates central tolerance in TCR-PLP1PlpWT mice completely.
4. Central tolerance induction to PLP is restricted to a distinct time window starting a
few days after birth. After 6 weeks, central tolerance to PLP is lost.
4.1 Central tolerance to PLP is induced by clonal deletion
and concomitant Treg induction of TCR-PLP1+ T cells
Characterisation of the phenotype of TCR-PLP1PlpWT mice in the thymus revealed that
the presence of the antigen PLP induced tolerance to TCR-PLP1-speciﬁc T cells. We
observed TCR-PLP1+ T-cells to be partly deleted and a fraction concomitantly redirected
into the Treg lineage.
In some TCR transgenic models, a dominant mode of tolerance induction was observed.
Either T cells were predominantly deleted or in addition to deletion also deviated into the
Treg lineage. In the Dep x hCRP mouse model, for instance, clonal deletion of the speciﬁc
transgenic T cells dominated the thymic phenotype of tolerance induction [85]. In other
models, such as the TCR-HA x AIRE-HA model [74], deviation of antigen-speciﬁc T cells
into the Treg lineage concomitant to the deletion was often observed. Likewise, in the TCR-
PLP1 model, we observed clonal deletion concomitant to deviation of regulatory T cells as
mode of tolerance induction to PLP. Furthermore, T cells speciﬁc to PLP9-20 were deleted
at the CD4SP stage of T cell development, unlike, for instance, hCRP-speciﬁc T cells which
were deleted at an early DP stage [85].
4.2 Medullary thymic epithelial cells express and present the
antigen PLP autonomously
We detected PLP transcripts in all thymic epithelium subsets, namely cTECs, immature and
mature mTECs (mTECslo and mTEChi, respectively), as well as in thymic DCs, albeit to
a smaller degree (Fig. 13). This expression pattern was in line with previous reports [1,3].
Due to its expression also in cTECs and DCs, PLP is referred to as an atypical tissue-
restricted antigen (TRA), since a typical TRA would be expressed only by AIRE+ mTEChi
cells [1]. Therefore, we investigated if the expression of PLP in the individual thymic APC
subsets was crucial for tolerance induction to TCR-PLP1+ T cells.
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EXPRESSION OF PLP. In order to delineate the role of PLP expression by APCs
of the hematopoietic (DCs, B cells) or non-hematopoietic compartment (TECs), we per-
formed transplantation experiments, in which selectively cells of the hematopoietic or non-
hematopoietic compartment lacked PLP expression. When cells of non-hematopoietic origin
were suﬃcient for PLP, deletion and Treg induction of TCR-PLP1+ T cells was detected.
In contrast, when PLP was only expressed by cells of the hematopoietic compartment,
TCR-PLP1+ T cells were not tolerised (Fig. 14). This indicated that PLP expression by
hematopoietic cells was not crucial for tolerance induction to PLP.
To prove a crucial role for TECs in PLP expression needed for tolerance induction, we
employed an additional system where PLP expression was absent only in thymic epithelial
cells due to the Foxn1-Cre-driven excision of the ﬂoxed Plp gene. In TCR-PLP1Plpﬂ/ﬂ
Foxn1-Cre mice, we observed a complete loss of tolerance towards TCR-PLP1+ T cells in
the thymus when PLP expression was abolished in TECs (Fig. 15). Thus, expression of
PLP by the remaining thymic dendritic cells and/or B cells did not lead to tolerance in-
duction in the thymus and revealed a crucial role for TECs in PLP-expression for tolerance
induction. As PLP expression was ablated in all Foxn1-expressing cells (TECs), we could
not diﬀerentiate between cTECs and mTECs and decipher their individual contribution to
PLP tolerance induction. Some studies have suggested that cTECs cannot induce tolerance
to self-antigens [158–160], whereas others have stated the opposite [161–164]. It has previ-
ously been reported that cTECs can also mediate clonal deletion of auto-reactive T cells,
although rather for T cells speciﬁc for “ubiquitous” self-antigens [165]. Furthermore, the
group of Kristin Hogquist has stated that cTECs were not the major player in the induction
of apoptosis in the cortex, but rather depended on a contribution from cortical dendritic
cells [43]. Even though we cannot formally exclude a role of cTECs for tolerance induction
to PLP, we think it is rather unlikely, as TCR-PLP1PlpWT and TCR-PLP1PlpKO animals
showed equal numbers of DP cells in the thymus, indicating no deletion in the cortex. Re-
cent work revealed that in the cortex, more than 50% of all signalling thymocytes at the
DP stage are deleted by strong signals of high-aﬃnity ligands that induce rapid apopto-
sis [166–169]. If PLP-speciﬁc T cells were not deleted in the cortex at the DP stage, it
is likely that the expression of PLP in cTECs does not result in the expression of exactly
the same epitope as in thymic DCs or in mTECs. Through the use of the unique lysoso-
mal proteases cathepsin L and thymus-speciﬁc serine protease (TSSP), cTECs possess a
unique processing machinery for the generation of “private peptides” [7, 170–172]. There-
fore, cTECs might display diﬀerent epitopes of PLP for cortical selection and therefore,
selection of PLP9-20-reactive T cells will only occur at the CD4SP stage in the medulla. It
remains interesting, though, why cTECs and DCs express PLP9-20 mRNA, although they
seem not to contribute to tolerance induction.
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PRESENTATION OF PLP. Antigens expressed by TECs may be transferred to and
presented by thymic DCs [82, 83]. Albeit we have seen the expression of PLP by DCs
not to be crucial for tolerance induction, DCs might still play a role in the presentation
of PLP. To address the contribution of intercellular PLP transfer from mTECs to DCs,
we analysed the T cell development in TCR-PLP1PlpWT mice deﬁcient for dendritic cells
(TCR-PLP1PlpWTDC): No diﬀerence in tolerance induction was observed in the presence
or absence of DCs (Fig. 16). This indicated that tolerance induction to PLP did not require
the physical presence of DCs, nor an antigen transfer of PLP to DCs.
Migratory DCs (such as plasmacytoid DCs and Sirp+ DCs) are capable of taking up and
transporting circulating antigen to the thymus [60, 173]. In TCR-PLP1Plpﬂ/ﬂ Foxn1-Cre
animals, in which only TECs are deﬁcient for PLP expression, no contribution of DCs in
PLP presentation was observed (Fig. 15). Therefore, we also excluded a contribution of
migratory DCs which could have taken up PLP in the periphery and presented the imported
PLP in the thymus [8]. However, we cannot diﬀerentiate whether migratory DCs did not
transport peripheral PLP to the thymus, or if all DC subsets are unable to present PLP
for tolerance induction. The necessity of antigen transfer of a particular mTEC-derived
antigen to dendritic cells for presentation may depend on the frequency or thymic locali-
sation of mTECs that express the antigen, or the amount of antigen expressed. PLP is a
tissue-restricted antigen and it is believed that only 1-3% of mTECs express the respective
antigen [1,80]. Therefore, it is somewhat surprising that PLP presentation is not maximised
by antigen-spreading to DCs in order to increase the likelihood of cognate antigen-encounter
for thymocytes. Yet the necessity for cross-presentation seems to be very individual for each
antigen and cannot be generalised.
Formally, we still need to show that the conditional deletion of PLP expression in TCR-
PLP1Plpﬂ/ﬂ Foxn1-Cre mice, was truly deleting all PLP expression in TECs. In situ hy-
bridisation for PLP would represent a good tool to visualise the lack of PLP expression in
TECs. However we are conﬁdent of a high deletion rate of PLP as residual expression of
PLP in TECs would promote tolerance induction, which was completely absent in these
animals.
Having excluded cross-presentation of PLP by dendritic cells, we next addressed direct
presentation of PLP by mTECs. In C2TAkd mice, the presentation capacity of mTECs
is reduced by an AIRE-promoter-driven knockdown of the MHC class II transactivator
(C2TA) [77]. Interference with the MHCII expression on mTECs, led to a reduced tolerance
induction to PLP in TCR-PLP1PlpWT C2TAkd mice (Fig. 17). This showed that mTECs
present the antigen PLP autonomously to T cells and induce clonal deletion as well as
deviation of PLP-speciﬁc T cells into the Treg lineage. We did not observe an absolute loss
of tolerance in TCR-PLP1PlpWT C2TAkd mice, but only a reduction of the phenotype. As
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the C2TAkd approach did not entirely eliminate MHCII from mTECs but only diminished
its surface density to approximately 10% of WT levels, the residual MHCII molecules in
TCR-PLP1PlpWT C2TAkd mice might be still suﬃcient to censor part of the TCR-PLP1+
T cells. It was speculated that in C2TAkd mTECs with diminished MHCII expression,
preferably CD4+ T cells at the very high end of the aﬃnity spectrum were tolerised by
the remaining 10% of pMHCII molecules [77]. In favour of this, the TCR-PLP1 T cell
receptor seems to fall into the category of high-aﬃnity receptors, as we have observed that
already PLP9-20 peptide in the femtogram-range triggered a stimulation of CD4+ TCR-
PLP1+ peripheral T cells in an in vitro stimulation assay (data not shown). The other
possibility is that cTECs do have an inﬂuence on tolerance induction to PLP, which will
only become apparent when the contribution of mTECs is diminished.
Collectively, we have shown that mTECs express and present the antigen PLP directly to
auto-reactive T cells and that DCs do not contribute to tolerance induction to PLP.
Also in other models, such as the AIRE-OVA x DO11.10 system [77] or the AIRE-HA x
TCR-HA system [74], in which mTECs had an autonomous role in antigen presentation,
DCs were found to be dispensable for tolerance induction. These models have conﬁrmed
the ability of mTECs to eﬃciently present antigens themselves and had previously given
rise to the hypothesis that the type of APC will ultimately determine the mode of toler-
ance induction. Currently, two main theories want to explain diﬀerences in fate choices of
auto-reactive T cells: One hypothesis is that the fate decision of an auto-reactive T cell is
determined by the aﬃnity with which the TCR binds to pMHC [151]. The other model pos-
tulates that the avidity of the TCR:pMHC interactions is relevant [174,175]. The C2TAkd
model developed by Hinterberger et al. argued in favour of the avidity hypothesis. In a
TCR-transgenic model system with diminished MHCII-restricted antigen presentation by
mTECs, the eﬃcacy of negative selection shifted more to the induction of Treg cells, when
all other parameters such as the amount and tissue speciﬁcity of antigen expression and
the responding thymocyte population were kept identical and potential cross-presentation
by DCs was excluded [77]. In our TCR-PLP1 transgenic model, we have observed that
PLP-speciﬁc T cells carrying the same TCR were deleted as well as redirected into the
Treg lineage, both mediated by mTECs (Fig. 16). Diminishing the presentation of PLP on
mTECs by crossing the C2TAkd mouse to our TCR-PLP1 model, resulted in a pronounced
escape of auto-reactive T cells into the periphery (Fig. 17). This break down of central
tolerance was in this case due to reduced pMHCII on mTEChi as all other parameters were
kept constant. This observation in the TCR-PLP1 model also argues towards the avidity
model (number of pMHC-TCR interactions) and against the aﬃnity model as the quality
of the interactions was not altered.
In other TCR-transgenic models, the antigen presentation by DCs was dispensable but not
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absent. In the AIRE-GCL x Dep transgenic system, for instance, indirect presentation
by DCs was not essential for negative selection in vivo, yet operated in parallel with the
direct presentation by mTECs [176]. This redundancy was then suggested to give central
tolerance a certain robustness [66]. With the TCR-PLP1 mouse model, we show for the
ﬁrst time that mTECs are not only capable of directly present antigen for ensuring both
modes of tolerance induction, but that the expression and presentation of an antigen by
mTECs is crucial for tolerance induction and that DCs did not play a role in induction of
tolerance to this antigen. Thus, we have shown with our model an example for an exclusive
role of mTECs in inducing tolerance to a self-antigen of the periphery. In the polyclonal
system, Perry et al. [86] demonstrated that DCs and mTECs play non-redundant roles in
deletion and Treg cell selection. The notion for redundancy between mTECs and DCs in
tolerance induction was mostly formed by fate decision analysis in TCR-transgenic models
with an introduced neo-self-antigen. By the genetic introduction of neo-self-antigens, it is
likely that the expression levels were higher than physiological conditions. Therefore, the
suggested redundant roles for mTECs and DCs in inducing central tolerance to these anti-
gens may have been caused by atypical expression levels. High expression of an antigen on
mTECs might favour an additional cross-presentation by DCs, while antigen expression at
physiological levels would potential limit tolerance induction to mTECs only. In favour of
this explanation is the observation of an essential role of mTECs in the AIRE-GCLlo x Dep
system. Here, the antigen GCL (GFP-C-reactive protein-Light chain 3-fusion protein) was
expressed at roughly fourfold lower mRNA levels when compared with AIRE-GCL mice,
and in contrast to the latter, mTECs were shown to be crucial for tolerance due to the
autophagy-dependent mode of direct presentation [176].
Thus, our ﬁndings have implications for the previously suggested redundancy in the roles
of thymic APCs for central tolerance induction. It is possible to think about a demarcation
between a crucial role of mTECs versus thymic dendritic cells dependent on the extent of
antigen expression. Perry et al. [86] suggested that tolerance to rare tissue-restricted anti-
gens are preferentially mediated by mTECs, while DCs mediate tolerance to more frequent
antigens. PLP is assumed to be expressed at low levels [65], and hence, is in line with this
suggestion.
Klein et al. [3] have reported that tolerance to PLP was established equally well in bone
marrow chimerae with PLP suﬃciency in both the TEC compartment or in cells of the
hematopoietic compartment. As they immunised mice with whole PLP protein and mea-
sured the recall response of peripheral T cells, they did not have the possibility to distinguish
between central and peripheral tolerance nor between tolerance to individual epitopes. We,
in contrast, have the ability to a) delineate the contributions of APC types to tolerance in-
duction speciﬁcally to the epitope PLP11-18, and to b) trace the fate of PLP-speciﬁc T cells
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ﬁrst in the thymus, and then, to follow these cells into the periphery in order to further assess
the inﬂuence of tolerance mechanisms there. In the thymus, we have seen TCR-PLP1+ T
cells to be deleted and deviated into the Treg lineage. In the periphery of TCR-PLP1Plpﬂ/ﬂ
Foxn1-Cre animals, we have observed clonal deletion acting on TCR-PLP1+ T cells that
have previously not been tolerised in the thymus due to the absence of PLP expression in
TECs (data not shown). Thus, additional negative selection in the periphery has shaped
the TCR-PLP1+ T cell pool. Furthermore, preliminary data have indicated that beside
negative selection, peripheral TCR-PLP1+ T cells, which have escaped thymic selection
in TCR-PLP1PlpWT mice, adopt an anergic phenotype and no longer responded to PLP
stimulation (data not shown). Moreover, we have been able to determine that the cell
type presenting PLP in the periphery is of hematopoietic origin (data not shown). Thus,
it is feasible that DCs or other APCs of bone marrow origin present PLP to peripheral
TCR-PLP1+ T cells and induce anergy as an additional dominant tolerance mechanism.
However, further investigations are necessary to characterise the putative peripheral toler-
ance mechanism in more detail.
Notwithstanding, we may conclude that tolerance induction to PLP is a combination of
central tolerance in the thymus (clonal deletion and deviation into the regulatory T cell
lineage) with additional tolerance mechanisms in the periphery, such as further clonal dele-
tion and anergy [7].
In a situation where peripheral tolerance accounts for the only tolerance mechanism to PLP,
the dimension of these mechanisms will become apparent. If it is not possible to elicit EAE
in TCR-PLP1Plpﬂ/ﬂ Foxn1-Cre animals, that did not show central tolerance, peripheral
tolerance mechanisms must be very potent and represent a second layer of tolerance induc-
tion.
Furthermore, tolerance mechanisms to the other epitopes of PLP may very well depend on
cells of the hematopoietic compartment. The proposition by Klein et al. [3] was that cells
of the non-hematopoietic compartment as well as cells of bone marrow origin mediated tol-
erance to PLP. This conclusion may come from the combination of central and peripheral
tolerance together or reﬂect the fact that the APC type mediating tolerance to a given
PLP epitope is highly individual. While we have conclusively shown in this study that
dendritic cells do not mediate central tolerance to epitope PLP11-18, tolerance induction to
the other PLP epitopes in the context of I-Ab might very well depend on the expression
and/or presentation by hematopoietic cells and would need to be assessed on an individual
basis.
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4.3 AIRE deﬁciency abrogates central tolerance in
TCR-PLP1PlpWT mice
Lack of AIRE selectively abolishes the antigen reservoir function of mTECs for AIRE-
dependent TRAs [2,90]. We have seen that central tolerance induction to PLP9-20 is greatly
impaired in the absence of AIRE. As we have shown that PLP was not expressed only in
mTEChi but also in cTECs, thymic DCs, and mTEClo, it was not entirely expected to see
a complete loss of tolerance induction to PLP in TCR-PLP1PlpWT AireKO animals (Fig.
19). When we quantiﬁed the mRNA expression of PLP in mTEChi, we detected a 6-fold
reduction of PLP mRNA expression in AireKO mTEChi compared to WT mTEChi (Fig. 18).
Therefore, we concluded that AIRE controlled tolerance to PLP, although we cannot base
this result on the simple explanation of an AIRE-dependent control of expression, as PLP
is also expressed AIRE-independently in cTECs and mTEClo (Fig. 13). Future quantiﬁ-
cation of PLP mRNA expression with respect to the presence of AIRE should also include
cTEC and mTEClo, and further discriminate between AIRE-positive and AIRE-negative
mTEChi.
Even though the expression of PLP might not be totally dependent on AIRE, we do see a re-
duction of PLP mRNA in AireKO mTEChi. Thus, while mTEClo also express PLP mRNA,
only mTEChi may be relevant for tolerance induction. We propose three hypotheses that
are not mutually exclusive to explain an inﬂuence of AIRE on the tolerance induction to
PLP.
First, there might be a critical threshold of antigen expression necessary for tolerance in-
duction. Thus, the expression of PLP by mTECs possibly lies slightly above this critical
threshold and in the case of AIRE deﬁciency, the amount of transcribed PLP mRNA by
mTEChi falls below this threshold, subsequently, leading to a breakdown of central toler-
ance to PLP.
Second, AIRE might have more inﬂuence than purely regulating the transcriptional land-
scape of TRAs. There is evidence that AIRE is also involved in the translation and/or
presentation of antigens. Kuroda et al. [104] described in their study, that the transcrip-
tion of alpha-foldrin retained the same levels in AireWT and in AireKO mice, while the
protein translation was aﬀected by AIRE deﬁciency. Also Hubert et al. [177] stated that
AIRE regulates aspects of antigen presentation, namely the antigen transfer from mTECs
to dendritic cells. Although we have shown for the antigen PLP9-20 that presentation by
thymic DCs did not play a role, AIRE might aﬀect the synthesis of PLP protein or the
presentation of the antigen by mTEChi. The next step to decipher the inﬂuence of AIRE
in tolerance induction to PLP would be to compare the amount of PLP protein in AireKO
versus WT TEC populations. To see a direct eﬀect of AIRE on PLP presentation, we would
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need to establish a sensitive ex vivo presentation assay to measure even small changes in
the presentation of PLP by mTECs.
Third, loss of tolerance with AIRE deﬁciency could possibly also reﬂect a problem of T cells
to scan eﬃciently the rare mTECs that present PLP. It was reported that the chemokine
landscape changes with the absence of AIRE [90,108]. Thus, a change in chemokines could
potentially inﬂuence the interaction of thymocytes with mTECs, modifying their migration
behaviour or the length of their contacts with stromal cells, leading to a loss of tolerance
induction [178,179].
Presented data are summarised in a graphical scheme in Figure 23.
4.4 Central tolerance induction to PLP is restricted to a
distinct time-window
Remarkably, we found tolerance to PLP in TCR-PLP1PlpWT mice to be dependent on
the age of the thymus. We have identiﬁed a time window for negative selection and de-
viation of auto-reactive T cells into the Treg lineage. Only a few days after birth, we
detected clonal deletion of PLP-speciﬁc T cells in the thymic compartment of CD4SP cells
in TCR-PLP1PlpWT mice. Furthermore, we demonstrated that induction of regulatory T
cells does not occur before the end of the ﬁrst week. At day 7, Tregs started to accumulate
in TCR-PLP1PlpWT mice, consistent with other publications reporting the emergence of
Tregs between day 4 and day 5 [156, 180]. For the development of Tregs, a two-step model
was proposed. First, an “instructive” phase up-regulates CD25 on the cell surface, which is
dependent on the TCR and favours self-reactive TCR speciﬁcities. Then, a second phase,
the “consolidation” phase, occurs in which expression of Foxp3 starts driven by cytokines
independently of the TCR [181]. The time required to complete this two-step process may
be reﬂected in the later emergence of Foxp3+ regulatory T cells.
We detected maximal clonal deletion and selection of regulatory T cells at 2 weeks. Strik-
ingly, tolerance induction was then lost completely at 6 weeks, regardless of whether the
antigen was present or absent in the thymus. Whether this is a peculiarity of the TCR-
PLP1 transgenic mouse or a phenomenon also observed in other model systems, has to be
further investigated.
A ﬁrst possible explanation for a loss of tolerance was reduced amounts of PLP: either a
reduction of PLP expression on the mRNA level, or a diminished PLP synthesis rate on the
protein level. Since a tissue-restricted antigen, such as PLP, is only presented by 1-3% of
mTECs [1,80], a further reduction of PLP could then lead to insuﬃcient antigen encounters
to induce tolerance. The quantiﬁcation of PLP mRNA revealed no signiﬁcant diﬀerences
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Figure 23: Graphical summary of tolerance induction to PLP in the young thymus. In the
young thymus, expression of the antigen PLP only by mTECs is relevant for tolerance induction. Thymic
DCs do not take part in central tolerance induction to PLP and antigen transfer from mTECs to DCs does
not happen. The expression of PLP mRNA in mTEChi cells is dependent on AIRE, whether the translation
of PLP protein also depends on AIRE is under investigation. To what extent the presentation of PLP relies
on AIRE still needs to be elucidated but might have also an eﬀect. In TCR-PLP1PlpWT animals, the main
portion of TCR-PLP1+ T cells that have seen PLP presented by mTECs are either redirected into the
regulatory T cell lineage or are deleted by apoptosis. Only very few TCR-PLP1+ T cells escape thymic
selection and egress into the periphery as naive T cells.
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between young and old thymi, therefore, we conclude that changes in expression would not
account for the loss of tolerance in adult TCR-PLP1PlpWT mice (Fig. 22). Alternatively,
an age-dependent decline of PLP protein synthesis could also be responsible for the loss
of tolerance. At the moment, we are in the process of collecting material of thymic APC
subsets mTEClo, mTEChi, cTECs, and thymic DCs from young and old animals to assess
the amount of PLP protein by Western blotting.
We considered additional factors that may change with time causing a loss of tolerance
induction to PLP with age: (1) Diﬀerences in the presentation of PLP in old thymi, (2)
a diﬀerent hormone status with adulthood , or (3) a change in the composition of thymic
APCs and the size of niches.
(1) Besides a possible reduction of the PLP protein, the presentation capacity of mTECs
could also be gradually reduced, eventually falling under a certain threshold where central
tolerance induction fails. As we have observed a diminished but still present tolerance
induction in TCR-PLP1PlpWT C2TAkd mice (Fig. 17), where MHCII surface molecules
had been reduced to 10%, a gradual reduction of the presentation capacity of mTECs is
unlikely to be the only reason for the entire loss of central tolerance to PLP. It is more
likely that a combination of several eﬀects abrogates the tolerance induction to PLP with
age. To address reduced presentation of PLP, again, we would need to develop an ex vivo
presentation assay with high sensitivity. The amount of PLP presented on ex vivo isolated
mTECs may be under the detection threshold, as the expression of a given TRA seems to
be conﬁned to only a small fraction (only 1-3%) of mTECs [1,80,85,182]. A sensitive assay
that detects quantitative diﬀerences in the nature of TCR:pMHC contacts would therefore
be needed. It might be possible to take advantage of measuring the Ca2+-inﬂux downstream
of the TCR when TCR-PLP1+ T cells see their cognate antigen on APCs. Whether such
an assay would be feasible for detection of PLP presentation on rare mTECs, or even the
gradual loss of it, remains undetermined.
(2) Thymic involution is closely associated with immunosenescence, a degeneration of the
immune system. It is widely accepted that with age the thymus undergoes changes called
involution, which are characterised by a progressive decline in thymus size and structure,
and eventually leads to the reduction in de novo generation of T cells [183]. It was published
that sexual hormones, that rise with the entry into puberty, partly drive the decrease of
thymic elements, eventually leading to age-related involution [184–188]. Especially a critical
role of testosterone on thymic involution has been reported [185]. As tolerance to PLP in
TCR-PLP1PlpWT mice vanished at the age of 6 weeks, which is marked as the entrance
to adulthood, we speculated whether modiﬁed levels of sexual hormones had evoked the
change in tolerance induction. To counteract changes in the hormone levels by puberty, we
castrated male TCR-PLP1PlpWT mice, since it was described that various defects in stromal
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turnover that accompanied involution were rapidly reversed following the ablation of the
sex steroids [189]. However, we did not observe any change in the phenotype nor a delay in
the loss of tolerance (data not shown). Also, no diﬀerences in tolerance induction to PLP
between males and females were obvious. For this reason, we dismissed the explanation of
a hormonal inﬂuence on thymic composition or cell interactions for the loss of tolerance.
(3) As third possibility, we considered that changes in the thymic composition could cause
a loss of tolerance to PLP. These changes could be a) a change in thymic niches relevant
for PLP, or b) a diﬀerential composition of AIRE-expressing cells. Developing thymocytes
compose the largest cell population in the thymus. If T cell progenitors continue to ingress
into the thymus while the thymus is not growing proportionally, thymocytes will then ﬁnd
themselves in a competitive situation for scanning all antigens displayed on mTECs and
thymic DCs. Here, it is to be noted that the presentation of PLP is not enlarged by antigen
hand-over to thymic DCs and, additionally, may further be restricted to a very limited
number of mTECs due to stochastic ﬂuctuations in promiscuous gene expression [99, 190].
It was found that the turnover of thymic epithelium happened quickly and frequently, but
later diminished upon thymic involution [189]. Thus, it is possible that with a higher ratio
of T cells : TECs, TCR-PLP1+ T cells start to compete for interaction with mTECs for
negative selection in the medulla [191, 192]. Because of limited access to PLP on mTECs,
intraclonal competition might then restrict the extent of induced tolerance to PLP.
Furthermore, the composition within the thymic epithelial cell population might be chang-
ing with time. The expression level of PLP on a per cell basis might be constant, but
the abundance of cells able to induce tolerance might decrease with time in the thymus,
causing the loss of phenotype in aged TCR-PLP1 mice. To test this hypothesis, we need a)
to further analyse the composition of the thymic subsets in young versus old TCR-PLP1
transgenic animals discriminating between Aire+/+ and Aire-/- subsets, and b) to measure
the abundance of AIRE protein and PLP protein over time. In preliminary data, we have
seen that the proportion of AIRE-expressing cells within the mTEC population diminished
signiﬁcantly within the ﬁrst 2 weeks (data not shown). Thus, it is feasible to speculate that
AIRE-expressing mTEChi become less numerous within an aging thymus. Moreover, it was
described that AIRE expression has a pro-apoptotic eﬀect, as AIRE+ mTECs in particular
have a relatively fast turnover with an estimated half-life of 2 weeks [63,193]. Therefore, we
wondered if the loss of thymic tolerance after 6 weeks might be linked to a progressive loss of
mTEChi cells or even only AIRE-expressing mTEChi. As we have seen that PLP expression
in mTEChi was controlled by AIRE, a progressive loss of AIRE-expressing mTEChi would
then also lead to a reduced PLP expression in the total thymus (see Fig. 24). Further inves-
tigations will help to clarify if the change in tolerance was due to less PLP presented or to
fewer cells capable of presenting PLP eﬃciently. To formally test the crucial involvement of
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mature AIRE-expressing mTEChi, we could block the development of mature mTEChi, as it
was recently published that in vivo administration of an anti-RANKL antibody selectively
blocked the generation of AIRE+ mTEChi [194]. Alternatively, TNF receptor-associated
factor 6 (TRAF6)-deﬁcient mice were shown to lack AIRE+ mTECs [46] and could repre-
sent a good tool to study the contribution of AIRE+ mTEChi for tolerance induction to
PLP.
mTEClo
mTEChi
10 days 6 weeks 10 weeks
threshold for 
tolerance induction
relative 
mRNA expression / cell
abundance of cell types
presentation of 
PLP/ thymus
Figure 24: Hypothesised link between the composition of the thymic compartment in regards
to a change in the ratio of mTEClo to mTEChi populations and PLP presented per thymus
inducing tolerance, while PLP expression on a per cell basis remained constant.
First row: The relative mRNA expression of PLP/cell is depicted here for mTEClo cells in black and
mTEChi cells in blue. The PLP expression did not change in these thymic subsets between young and old
mice signiﬁcantly, represented here as even bars.
Second row: Change of the ratio mTEClo : mTEChi. With aging, the relative abundance of the mTEChi
population in all TECs is decreasing.
Third row: Hypothesised amount of PLP being presented in the thymus. With a decrease in mTEChi, the
amount of presented PLP is reduced. Further assuming that there is a critical threshold of PLP presentation
for eﬃcient tolerance induction, the loss of tolerance with age in TCR-PLP1PlpWT mice could be explained
by a reduction of mTEChi cells able to present PLP to TCR-PLP1+ T cells.
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4.5 Summary
We generated a TCR-transgenic mouse model which allowed us to visualise central tolerance
mechanisms towards the endogenous tissue-restricted antigen PLP, which is expressed at
physiological levels in the thymus. We found PLP9-20-speciﬁc T cells to be tolerised by
clonal deletion and concomitant deviation into the regulatory T cell lineage. Furthermore,
presented data show that mTEC-driven expression of the endogenous antigen PLP mediates
tolerance induction in an autonomous manner, whereas thymic DCs were dispensable for
central tolerance induction to PLP. We could also provide the ﬁrst evidence, that central
tolerance might act in a certain time window: In the TCR-PLP1 mouse model, deletion of T
cells started from day 3, while regulatory T cells accumulated not before 1 week after birth.
At the age of 6 weeks we observed a breakdown of central tolerance induction. It remains
to be determined if this loss of tolerance is linked to changes in thymic composition, and if
there are additional tolerance mechanisms acting in the periphery to maintain tolerance.
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5.1 Genotyping
For genotyping, mouse tails were digested in 50 L digestion buﬀer for 5 hours at 55℃,
followed by proteinase K heat inactivation at 95℃ for 5 minutes. Subsequently, 1 L of the
digested tail DNA was used for genotyping. Genotyping reactions for the TCR-PLP1 -
and -transgenes as well as for the PLP-gene were carried out using the TD58x30 program
(see table 1). PCR reactions for genotyping CD11c-Cre, DTA, AireKO, PLPﬂ/ﬂ, Foxn1-Cre,
and C2TAkd followed the PCR program TD54x30.
5.2 Immunisation
Mice were immunised with 50 g to 100 g peptide or protein emulsiﬁed in complete
Freund’s adjuvant (cFA). The amount of peptide was taken up in 50 L PBS and mixed
with 50 L of cFA by soniﬁcation. 50 L of this emulsion was subsequently injected sub-
cutaneously into the footpad of the hindleg of the mouse. To analyse the T cell response in
a proliferation assay, the immunised mouse was sacriﬁced 8-9 days post immunisation and
the draining lymph nodes (poplietal and inguinal) were removed for analysis.
5.3 In vitro restimulation
After immunisation, the inguinal and poplietal lymph nodes were removed, pooled and
single cell suspensions were cultured in 24-well plates at a concentration of 4 x 106/mL in
the presence of 5 g/mL PLP9-20 peptide in cIMDMmedium (see table 8). At day 3 and day
7 of culture, 20 U/mL recominbant human IL-2 (hIL2) were added and the culture volume
was increased to 2 mL/well. T cells were restimulated every 10 days with 50.000 T cells/well
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Table 1: PCR program used for genotyping.
Table 2: Genotyping program TD58x30.
Temperature Time
(min:sec)
94℃ 3:00
94℃ 0:45 |
64℃ 0:45 |2x
72℃ 1:00 |
94℃ 0:45 |
62℃ 0:45 |2x
72℃ 1:00 |
94℃ 0:45 |
60℃ 0:45 |2x
72℃ 1:00 |
94℃ 0:45 |
58℃ 0:45 |30x
72℃ 1:00 |
72℃ 5:00
15℃ forever
Table 3: Genotyping program TD54x30.
Temperature Time
(min:sec)
94℃ 3:00
94℃ 0:45 |
60℃ 0:45 |2x
72℃ 1:00 |
94℃ 0:45 |
58℃ 0:45 |2x
72℃ 1:00 |
94℃ 0:45 |
56℃ 0:45 |2x
72℃ 1:00 |
94℃ 0:45 |
54℃ 0:45 |30x
72℃ 1:00 |
72℃ 5:00
15℃ forever
with either 400.000 lethally irradiated (3000 rad) erythrocyte-depleted, syngenic splenocytes
or 30.000 lethally irradiated bone marrow-derived dendritic cells together with cognate
peptide. Again, at day 3 and day 7, 20 U/mL hIL2 were added.
5.4 3H-thymidine T cell proliferation assay
Proliferation of peripheral T cells was measured by incorporation of 3H-thymidine. To this
end, 4 x 105 pooled lymph node cells were cultured together with 3 x 104 irradiated BmDCs
per well in cHL-1 medium with titrated amounts of peptide. T cells were cultured in the
presence of cognate or non-cognate antigen for 4 days at 37℃ in round-bottom 96-well
plates. As a control for the eﬃcacy of immunisation, tuberculin puriﬁed protein derivate
(PPD) was used since immunisations were carried out using cFA which contains part of
mycobacterium tuberculosis in order to boost the immune response. T cell proliferation
was quantiﬁed after 48 h of culture by pulsing cells with 1 Ci 3H-thymidine/well for 20 h
before harvesting cells onto ﬁlters and determining the amount of incorporated radioactive-
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labelled thymidine using a BetaPlate liquid scintillation counter (Wallac, Gaithersburg,
MD). Results shown are expressed as mean counts per minute of duplicates or triplicates.
5.5 Culture of bone marrow-derived dendritic cells
(BmDCs)
Mice were anaesthetised and euthanised by cervical dislocation. Both hind legs were surgi-
cally removed, muscles were peeled oﬀ from tibia and femur and bones were transported in
PBS. After sterilisation of the bones in 70% ethanol for 1 min, both ends of the bone were
cut open and the bone marrow (Bm) was ﬂushed out with the help of a syringe under sterile
conditions. The Bm cell suspension was passed through a nylon cell strainer and red blood
cells were lysed in 10 mL ammonium chloride solution. After 2 washing steps, cells were
incubated in Petri dishes of 10 cm diameter in a concentration of 0.2 x 106 cells/mL and a
starting volume of 10 mL of cIMDM. Of note, the Petri-dishes were not coated for cell cul-
ture use. For a GM-CSF culture, cIMDM was complemented with 10 ng/mL recombinant
murine granulocyte/macrophages-colony stimulating factor (GM-CSF) (PeproTech). The
primary cells were cultured for 8 days in complete IMDM medium replenishing the medium
and cytokines after 3 and 6 days. At day 3, the culture volume was increased to 20 mL.
At day 6, it was possible to pulse BmDCs with protein, by adding the protein to the cell
culture in the desired concentration for a minimum of 6 hours. Before harvesting the next
day, BmDCs were matured by the addition of 300 ng/mL E.coli-derived LPS (Sigma).
BmDCs were then either directly used in a proliferation assay or frozen for later use. To
control the quality of the APCs, maturation markers as MHCII and CD80 can be monitored
by ﬂow cytometry.
5.6 Fusion of activated T cells to BW-NFAT-GFP
T cell hybridomas can be obtained by fusing activated T cells with the thymoma cell line
BW5147 that lacks inherent functional TCR chains. BW-NFAT-GFP cells were used as
fusion partner, which are a BW cell line that additionally carry a GFP reporter under the
NFAT promoter (kind gift of Dr. Dominic van Essen, Institute de Recherche sur le Cancer
et le Vieillissement, Nice). 3 days prior to fusion, T cells needed to be stimulated in order
to be activated and highly proliferating at the time for fusion. T cells were mixed with the
BW fusion partner in a ratio of 1 : 3. Then, 0.5 mL of pre-warmed polyethylene glycol 1500
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(PEG1500, Roche) was added slowly in order to initiate the two cell types to fuse. The
cell suspension was stirred gently for another minute before pre-warmed medium was added
drop-wise to gradually dilute the PEG solution. After diluting out the PEG, the cells were
taken up in fresh cIMDM and gently distributed onto ﬂat-bottom 96-well plates (roughly
100 L cell suspension/well). After 1 day of incubation, 2x HAT medium was added to
start the selection process. Due to the addition of aminopterin, the DNA de novo synthesis
in BW cells is blocked while fused BW cells have acquired the ability to synthesise DNA via
the “salvage pathway”. T cells alone cannot survive more than 5 days without continuous
supply of IL-2 and stimulus, and subsequently, die as well.
On day 3  5, most non-hybrid cells were dead, while hybrids start to grow in the selection
medium. After 10 days of culture, T cell hybridomas can be grown ﬁrst in cIMDM with
HT only and after weaning them of the supplements hypoxanthine/thymidine in normal
cIMDM.
5.7 Cloning
Genomic DNA was prepared from 1 x 106 D9-119-2 T hybridoma cells by digestion with
proteinase K (Sigma), followed by phenol extraction and precipitation with ethanol. The
speciﬁc primers that were used to amplify the genomic DNA encoding the TCR chains were
designed to start 70 base pairs upstream from the start codon for the TCR V3.2 chain and
30 base pairs upstream for the TCR V6 chain in order to include essential splice signals.
Both primer pairs also introduced speciﬁc restriction sites for later cloning.
The genomic DNA encoding the VJ- and VDJ-regions of the clone D9-119-2 TCR were
then cloned into the unique XmaI/SacI restriction site of the pT or the unique XhoI/SacII
restriction site of the pT cassette vector, generating the pTPLP1 and pTPLP1 trans-
gene expression constructs, respectively (Fig. 25). Cloning was veriﬁed by sequencing with
primer pairs for the constant C-region together with region in the TCR variable V3.2 or
TCR variable V6, respectively. Vector sequences were removed by enzymatic digestion
with restriction enzymes and these constructs were puriﬁed and sent for injection.
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Figure 25: Scheme of pT cassette vectors with designated restriction sites for cloning. pT
cassette vector and pT cassette vector are shown schematically with designated restriction sites to clone
the desired genomic variable TCR region. For pT cassette, the restriction enzymes XmaI and SacI, for
the pT cassette, the restriction enzymes XhoI and SacII were used. Scheme adapted from Kouskoﬀ et al.
(1995) [116].
5.8 Electroporation of transgenic constructs for veriﬁcation
into A5 cells
To stably express the transgenic pT cassette vectors in A5 or Dep cells, the cells were
electroporated at 250 mV with 25 g linearised pT cassette vector, 25 g linearised pT
cassette vector, together with 5 g linearised NFAT-GFP vector that contained a puromycin
resistance gene. The electroporated cells were plated in a 10 mL dish over night and plated
the next day into 96-well containing cDMEM medium supplemented with puromycin for
selection. The cells that were restistant to puromycin treatment, were selected and analysed
for TCR expression and stimulation.
5.9 IL-2 ELISA
The concentration of the cytokine IL-2 is often taken as measurement for stimulation and
T cell activation. IL-2 concentration was determined in culture supernatants of T cell
hybridoma cells stimulated by antigen primed BmDCs or splenocytes. The supernatant
was taken for analysis 72 hours after stimulation with peptide by quantitative capture
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ELISA according to the manufacturers guidelines (BD OptEIA™, BD Bioscience). Assays
were developed with TMB Microwell Peroxidase Substrate and read at 450 nm.
5.10 Phenotypic analysis
For phenotypic analysis of TCR-PLP1 transgenic mice, thymus and spleen were commin-
uted between two glass slides, ﬁltered with FACS buﬀer through a nylon mesh to remove
cell clusters, and cell numbers were determined by counting the cell suspension using a
CasyCounter machine (Innovatis).
5.11 Flow cytometric analysis
Surface staining was performed according to standard procedures at a density of 1-2 x 106
cells/ 50 L and volumes were scaled up accordingly. Cells were labelled with the respective
antibodies (see table 10) for 20 min on ice in the dark. Intracellular Foxp3 staining was
performed according to manufacturers instruction of the staining kit (eBioscience). Flow
cytometry measurements were performed on a FACS Canto II machine (Becton Dickinson)
using FACS DIVA software (BD) and FlowJo software (Treestar inc. USA) for analysis.
5.12 Deoxyguanosine treatment
E14 to E16 thymic lobes were placed on 0.45-mm nylon membrane (Millipore) swimming in
a 6-well culture plate ﬁlled with 6 mL of fresh 8% FCS supplemented cIMDM medium sup-
plemented with 1.35 mM 2-deoxyguanosine for the removal of all bone marrow derived cells.
The fetal thymic organ cultures (FTOCs) were incubated for 5 days prior to transplantation
under the kidney capsule of mice.
5.13 Transplantations
Recipient mice, 4   6 weeks of age, were narcotized with 200 L/10 g body weight of a
combination of ketamine (0.8 mg/mL, Ketavet, Pﬁzer) and xylazine (5 mg/mL, Rompun,
Bayer, Germany) in PBS. Their eyes were protected from light and from drying out with
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Bepanthen cream (Bayer, Germany). The site of incision was shaved and disinfected. A
small incision was made through skin and peritoneum. The kidney was lifted out and ﬁxed
at an exposed position. The fragile kidney capsule was carefully scratched with a scalpel.
Then, the capsule is lifted up with ﬁne forceps and the fetal thymic lobe was slipped
underneath the capsule. Then, the kidney is pushed back to its normal position, the sticky
peritoneum pulled back together, and the skin is stapled with 2   3 staples. Mice were
sacriﬁced 3.5 weeks later, and the grown transplanted thymi were analysed by FACS.
5.14 Isolation of thymic antigen presenting cells
Thymi were harvested and cleared from connective tissue and fat, cut into very small pieces
using scissors and resuspended in pre-warmed digestion medium. 1 mL digestion medium
was used per thymus. Digestion was performed in a round-bottom tube at 37℃. The cell
suspension was also pipetted up and down softly every 5 min to apply additionally some
mechanical force for better and faster digestion. After 35-35 min the cell suspension was
transferred to 4℃ and 0.01 volume of 0.5 M EDTA was added. After 5 min incubation time,
the cell suspension was ﬁltered and washed in FACS buﬀer and resuspended in Percoll™(
1.115; GE Healthcare). A second layer of Percoll ( 1.055) and a third layer of FACS buﬀer
was carefully added on top. After the layering, the gradient was centrifuged at 4℃ and
1350 g with slow acceleration and no break for 30 min. The upper interface, containing the
desired low density cell fraction, was harvested and washed in FACS buﬀer. Cells were now
ready for staining.
The Percoll density gradient solutions were prepared as follows:
Table 4: Percoll density gradient solution.
 1.115 (High density Percoll)  1.055 (Low density Percoll)
9 vol. Percoll stock ( 1.134) 1 vol. Percoll ( 1.115)
1 vol. PBS (10x) 1.09 vol PBS (1x)
25 mM HEPES pH=7.2 (ﬁnal)
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5.15 Assessment of EAE
Mice were examined for signs of EAE. The score of EAE was graded as follows:
Table 5: Classiﬁcation of assessment of EAE score.
Score appearance
0.5 tip of tail was ﬂaccid
1 complete tail was ﬂaccid
1.5 tail ﬂaccid and one foot is weak
2 1 foot is weak and eﬀect on the other leg can be seen.
2.5 one leg is completely limb
3 complete paralysis of both hind legs
3.5 mouse is moving on front legs only or even partially front leg paralysis;
when mouse is on its side, it has problems getting up
4 no moving but eating
after score 4 the mouse was saccriﬁced.
5.16 RNA isolation and quantitative real time PCR
(qRT-PCR)
Total RNA was isolated using the miRNeasy Kit (Qiagen). The concentration and quality
of the isolated RNA was determined by NanoDrop ND1000 (Thermo Scientiﬁc) accepting
a A260/A280 ratio of 2  0.2. The total RNA was subsequently used for cDNA synthesis
by iScript™cDNA Synthesis Kit (BioRad) in order to perform subsequently quantitative
real-time PCR (qRT-PCR). Both steps were conducted according to manufacturers proto-
col. Quantiﬁcation of mRNA expression was carried out using a C1000™ Thermal cycler
from BioRad (CFX96 Real-Time System). Biorads CFX Manager software was used for
analysis. Calculation of gene expression levels was carried out by using following formula:
Relative expression = 2Ct
Ct values represent the threshold cycle for each transcript detected and Ct represents the
diﬀerence between the threshold cycle for the housekeeping gene and the gene of interest
(housekeepinggene  geneofinterest). As housekeeping gene, hypoxanthine guanine phos-
phoribosyltransferase, HPRT, was used. Ct values relate the Ct diﬀerences between
the examined populations and the population used for normalisation (e.g. thymic DCs of
10-day old animals or mTEChi of WT animals).
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Program used for real time PCR:
Table 6: Protocol used for the real time PCR reactions.
Temperature Time
(min:s)
95℃ 0:30
95℃ 0:05 |
56℃ 0:10 |40x
65℃ 0:05
95℃ decreasing the temperature
in steps of 0.5℃ gradually
15℃ 0:20
4℃ forever
5.17 Statistical analysis
Data were ﬁrst tested for normality using the Kolmogorov-Smirnow (KS) and Shapiro-Wilk
test (Graphpad Prism Version 5.0c). All data with a group size large enough have passed
the normality test positively. Some groups were too small in size to perform an assessement
for normality, but were expected to distribute normally with a higher group size. Statistical
signiﬁcance for normally distributed data sets was then assessed by the two-tailed Students
t-test. Signiﬁcance was given when p<0.05.
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6.1 Mice
Mice were bred in the animal facility of the Institute of Immunology at the LMU Munich
in individually ventilated cages under speciﬁc pathogen free (SPF) conditions. C57BL/6
(B6) is an inbred strain of the Institute of Immunology. PLP-/- mice were obtained from
Klaus Nave from the Max-Planck-Institute for Experimental Medicine, Göttingen and are
described in Klugmann et al. [133].  DC mice were a kind gift of David Voehringer and
are described in Ohnmacht et al. [154]; AIRE-/- mice have been described in Ramsey et al.
(2002) [195]; C2TAkd mice were generated by Hinterberger et al. (2010) and are described
in [77]; Foxn1-Cre mice were described in Gordon (2007) [196]; PLPﬂ/ﬂ were kindly provided
by Hauke Werner, Max Planck Institute for Experimental Medicine, Göttingen.
The TCR-PLP1 transgenic mice were generated during this work. Pro-nuclear injections
for generating the TCR-PLP transgenic mouse, were performed by the transgenic animal
facility of the Max-Planck-Institute of Molecular Cell Biology and Genetics in Dresden by
Ronald Naumann. Local law regulation authorities approved all animal experiments.
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6.2 PLP peptides
PLP peptides were purchased at BioTrend in a quantity of 20 mg and a purity of >80%
(HPLC).
Table 7: Sequences of synthetic PLP peptides.
PLP peptide Sequence
PLP1-24 GLLECCARCLVGAPFASLVATGLC
PLP160-184 VVWLLVFACSAVPVYIYFNTWTTCQ
PLP192-216 TSASIGSLCADARMYGVLPWNAFPG
PLP224-248 LSICKTAEFQMTFHLFIAAFVGAAA
PLP9-20 CLVGAPFASLVA
PLP172-183 PVYIYFNTWTTC
6.3 Cell culture media with supplements
For all primary cell cultures, IMDM medium supplemented with the following reagents was
used and is in the following referred to as complete IMDM (cIMDM) medium. HL-1 medium
resembling cIMDM medium without the addition of FCS was used for proliferation assays.
Digestion medium including a mix of collagenase/dispase was crucial for TEC isolation.
cIMDM was supplemented with HAT as selection medium for freshly generated T cell
hybridoma.
Table 8: Ingredients for cell culture media complemented with the listed supplements.
Medium supplements
cIMDM 500 mL IMDM medium containing L-glutamine (GE Healthcare)
8% FCS (BioChrome)
1% L-glutamine (200 mM) with penicillin/streptomycine (100x)
(PAA)
1% MEM non-essential amino acids (100x) (PAA)
1 mM sodium pyruvate (Gibco)
50 M -Mercaptoethanol (Gibco)
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Medium supplements
cHL-1 500 mL HL-1 medium (Whittaker)
1% L-glutamine (200 mM) with penicillin/streptomycine (100x)
(PAA)
1% MEM non-essential amino acids (100x) (PAA)
1 mM sodium pyruvate (Gibco)
50 M -Mercaptoethanol (Gibco)
Digestion 500 mL RPMI medium
medium 0.2 mg/mL Collagenase (Roche)
for TEC isolation 0.2 mg/mL Dispase I (Roche)
2% FCS
25 mM HEPES (pH7.2)
25 g/mL DNase I (Roche)
HAT-selection 500 mL cIMDM medium
medium 12 mL hypoxanthine/thymidine (HT)
0.6 mL aminopterine
6.4 Buﬀers and solutions
All buﬀers and solutions were made with water puriﬁed in a Millipore ﬁlter system (pore
size 0.22 m) (Biocel). All chemicals met the highest purity level. Established chemicals
and laboratory equipment, which are not listed in the following, were obtained from Roth,
Sigma-Aldrich, Merck, Boerhinger Mannheim, Invitrogen and new England Biolabs inc.
Table 9: Composition of buﬀers and solutions.
Name Composition
Gitocher digestion buﬀer (10x) 670 mM Tris pH 8.8
166 mM ammonium sulfate
65 mM MgCl2
0.1% gelatin
Digestion buﬀer for tails 3 L proteinase K (10 mg/mL stock)
2.5 L Triton (10% stock)
5 L Gitocher Buﬀer (10x)
0.5 L -Mercaptoethanol
39 L H2O
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Name Composition
PCR Red-buﬀer (5x) 250 mM KCl
50 mM Tris pH 8.3
43% glycerol
7.5 mM MgCl2
2 mM Cresol Red
PBS (10x) 800 g NaCl
20 g KCl
115 g Na2HPO4  2 H2O
20 g KH2PO4
pH adjusted to 7:2  7:4
FACS Buﬀer 1x PBS
2% FCS
2 mM EDTA
Aminopterin (1000x) 17.6 mg aminopterine
5 mL 0.1 N NaOH
in 90 mL Aqua bidest
neutralise with 0.1 N HCl
keep at -20℃ in the dark
HT 272.2 mg hypoxanthine (2 mM)
77.5 mg thymidine (3.2 mM)
in 100 mL Aqua bidest
heat up to 50℃
add NaOH until powder dissolves
6.5 Antibodies
Table 10: List of all antibodies used in this study. All antibodies are listed with the respective clone
and conjugated ﬂuorophore.
Speciﬁcity Conjugate Clone Supplier
CD4 APCCy7 GK1.5 Biolegend
CD4 V500 RM-4-5 BD
CD8 PE/Cy5 53  6:7 Biolegend
CD24 Paciﬁc Blue M1/69 eBioscience
CD25 PE/Cy7 PC61 Biolegend
CD44 APC-Cy7 and APC IM7 Biolegend
CD62L APC MEL-14 Biolegend
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Speciﬁcity Conjugate Clone Supplier
CD69 PE-Cy7 H1.2F3 Biolegend
Foxp3 APC FJK-16s eBioscience
TCR V2 PE and Biotin B20.1 BD
TCR V3.2 FITC and Biotin RR3-16 BD
TCR V8.3 FITC B21.14 BD
TCR V11.1/11.2 PE RR8-1 BD
TCR V2 FITC and PE H57-597 BD
TCR V3 FITC KJ25 BD
TCR V4 FITC and PE KT4 BD
TCR V5.1 FITC and Biotin MR9-4 BD
TCR V6 FITC and PE RR4-7 Biolegend and BD
TCR V7 PE TR310 BD
TCR V8.1/8.2 FITC KJ16-133 eBioscience
TCR V8.3 PE IB3.3 BD
TCR V10 PE B21.5 BD
TCR V11 FITC RR3-15 BD
TCR V11 PE KT11 Biolegend
TCR V13 FITC MR12-3 BD
TCR V12 Biotin MR11-1 BD
TCR V14 FITC and Biotin 14-2 BD
TCR V17 FITC KJ23 BD
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6.6 Primer list
Primers used for genotyping:
Table 11: List of all primers used for genotyping. Sequence of forward and reverse primers are
indicated as fwd and rev, respectively.
Genotype Sequence 50 ! 30
PLPWT fwd GAAAGGTTCCATGGTCAAGG
PLPWT rev CTGTTTTGCGGCTGACTTTG
PLPKO rev CTTGCCGAATATCATGGTGG
TCR-PLP1 V3.2 fwd ACAACAGAGCTGCAGCCTTC
TCR-PLP1 V3.2 rev GCAGTGCTAGGAAGGGCGGC
TCR-PLP1 V6 fwd CCCAGAGCCAAAGAAAGTC
TCR-PLP1 V6 rev AGCCTGGTCCCTGAGCCGAA
PLP-ﬂoxed fwd GACATAGCCCTCAGTGTTCAGG
PLP-ﬂoxed rev GAATCCTGCATGGACAGACAG
C2TAkd fwd TAAATTCTGGCTGGCGTGG
C2TAkd rev ACCGGACTAGTGGAAAAGCGCCTCCCCTACC
CD11c-Cre fwd CGATGCAACGAGTGATGAGG
CD11c-Cre rev GCATTGCTGTCACTTGGTCGT
DTA fwd TACATCGCATCTTGGCCACG
DTA rev CCGACAATAAATACGACGCTG
Foxn1-Cre fwd CTCTCCTCCGAGTATCCAATCTG
Foxn1-Cre rev CCCTCACATCCTCAGGTTCAG
AIRE-KO fwd AAGCCGTCCAGGATGCTAT
AIRE-KO int GTCATGTTGACGGATCCAGGGTA
AIRE-KO rev AGACTAGGTGTTCCCTCCCAACC
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Primers used for real-time PCR, sequencing and cloning into the pT cassette vectors:
Table 12: List of all primers used for quantitative Real-time PCR and cloning. Sequence of
forward and reverse primers are indicated as fwd and rev, respectively.
Genotype Sequence 50 ! 30
PLP qRT-PCR fwd GGGCTTGTTAGAGTGTTGTGC
PLP qRT-PCR rev GAAGAAGAAAGAGGCAGTTCCA
HPRT qRT-PCR fwd TGAAGAGCTACTGTAATGATCAGTCAAC
HPRT qRT-PCR rev AGCAAGCTTGCAACCTTACCA
V3.2 fwd TCCTACTTTGGGACACCT
sequencing rev TTTCGGCACATTGATTT
V6 fwd TGCTGGGTAACCCTTTG
sequencing rev ACCTCCTTGCCATTCAC
pT cassette fwd ATCCCGGGCTTTCCTGCCTGTCCTGTTCCA
cloning rev ATGAGCTCGCAGTGCTAGGAAGGGCGGC
pT cassette fwd AAGTCGACCCAGAGCCAAAGAAAGTC
cloning rev TACCGCGGAGCCTGGTCCCTGAGCCGAA
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